<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Genes (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Genes (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">genes</journal-id>
<journal-title-group>
<journal-title>Genes</journal-title>
</journal-title-group>
<issn pub-type="epub">2073-4425</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29165379</article-id>
<article-id pub-id-type="pmc">5704252</article-id>
<article-id pub-id-type="doi">10.3390/genes8110339</article-id>
<article-id pub-id-type="publisher-id">genes-08-00339</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Role of Non-Coding RNAs in the Etiology of Bladder Cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gulìa</surname>
<given-names>Caterina</given-names>
</name>
<xref ref-type="aff" rid="af1-genes-08-00339">1</xref>
<xref ref-type="author-notes" rid="fn1-genes-08-00339">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baldassarra</surname>
<given-names>Stefano</given-names>
</name>
<xref ref-type="aff" rid="af1-genes-08-00339">1</xref>
<xref ref-type="author-notes" rid="fn1-genes-08-00339">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Signore</surname>
<given-names>Fabrizio</given-names>
</name>
<xref ref-type="aff" rid="af2-genes-08-00339">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rigon</surname>
<given-names>Giuliano</given-names>
</name>
<xref ref-type="aff" rid="af3-genes-08-00339">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pizzuti</surname>
<given-names>Valerio</given-names>
</name>
<xref ref-type="aff" rid="af4-genes-08-00339">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gaffi</surname>
<given-names>Marco</given-names>
</name>
<xref ref-type="aff" rid="af5-genes-08-00339">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Briganti</surname>
<given-names>Vito</given-names>
</name>
<xref ref-type="aff" rid="af5-genes-08-00339">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Porrello</surname>
<given-names>Alessandro</given-names>
</name>
<xref ref-type="aff" rid="af6-genes-08-00339">6</xref>
<xref ref-type="corresp" rid="c1-genes-08-00339">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7584-2171</contrib-id>
<name>
<surname>Piergentili</surname>
<given-names>Roberto</given-names>
</name>
<xref ref-type="aff" rid="af7-genes-08-00339">7</xref>
<xref ref-type="corresp" rid="c1-genes-08-00339">*</xref>
</contrib>
</contrib-group>
<aff id="af1-genes-08-00339"><label>1</label>Department of Gynecology, Obstetrics and Urology, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy; <email>85cate@live.it</email> (C.G.); <email>stefano.baldassarra@hotmail.it</email> (S.B.)</aff>
<aff id="af2-genes-08-00339"><label>2</label>Department of Obstetrics and Gynaecology, Misericordia Hospital, 58100 Grosseto, Italy; <email>fabri64@me.com</email></aff>
<aff id="af3-genes-08-00339"><label>3</label>Department of Obstetrics and Gynaecology, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, Italy; <email>darra80@hotmail.com</email></aff>
<aff id="af4-genes-08-00339"><label>4</label>Department of Urology, Misericordia Hospital, 58100 Grosseto, Italy; <email>vpizzuti@gmail.com</email></aff>
<aff id="af5-genes-08-00339"><label>5</label>Pediatric Surgery and Urology Unit, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, Italy; <email>marco.gaffi59@gmail.com</email> (M.G.); <email>vito.briganti@fastwebnet.it</email> (V.B.)</aff>
<aff id="af6-genes-08-00339"><label>6</label>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA</aff>
<aff id="af7-genes-08-00339"><label>7</label>Institute of Molecular Biology and Pathology, Italian National Research Council (CNR-IBPM), 00185 Rome, Italy</aff>
<author-notes>
<corresp id="c1-genes-08-00339"><label>*</label>Correspondence: <email>aporrelloresearch@yahoo.com</email> (A.P.); <email>roberto.piergentili@uniroma1.it</email> (R.P.); Tel.: +1-919-843-8227 (A.P.); +39-06-4991-2827 (R.P.)</corresp>
<fn id="fn1-genes-08-00339">
<label>†</label>
<p>These authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>11</month>
<year>2017</year>
</pub-date>
<volume>8</volume>
<issue>11</issue>
<elocation-id>339</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 by the authors.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>According to data of the International Agency for Research on Cancer and the World Health Organization (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organization Mortality), bladder is among the top ten body locations of cancer globally, with the highest incidence rates reported in Southern and Western Europe, North America, Northern Africa and Western Asia. Males (M) are more vulnerable to this disease than females (F), despite ample frequency variations in different countries, with a M:F ratio of 4.1:1 for incidence and 3.6:1 for mortality, worldwide. For a long time, bladder cancer was genetically classified through mutations of two genes, fibroblast growth factor receptor 3 (<italic>FGFR3</italic>, for low-grade, non-invasive papillary tumors) and tumor protein P53 (TP53, for high-grade, muscle-invasive tumors). However, more recently scientists have shown that this disease is far more complex, since genes directly involved are more than 150; so far, it has been described that altered gene expression (up- or down-regulation) may be present for up to 500 coding sequences in low-grade and up to 2300 in high-grade tumors. Non-coding RNAs are essential to explain, at least partially, this ample dysregulation. In this review, we summarize the present knowledge about long and short non-coding RNAs that have been linked to bladder cancer etiology.</p>
</abstract>
<kwd-group>
<kwd>
<italic>TP53</italic>
</kwd>
<kwd>
<italic>FGFR3</italic>
</kwd>
<kwd>microRNA</kwd>
<kwd>small non-coding RNA</kwd>
<kwd>long non-coding RNA</kwd>
<kwd>epigenetics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-genes-08-00339">
<title>1. Introduction</title>
<p>As stated by the US National Cancer Institute (NCI) [<xref ref-type="bibr" rid="B1-genes-08-00339">1</xref>], bladder cancer (BC) is the sixth most frequent type of cancer in the Western world, especially in the USA, in which it represents 4.7% of all new cancer cases. According to statistical projections, in 2017, there will be 79,030 new cases of BC and an estimated 16,870 individuals will die because of it. BC is most commonly diagnosed among people aged 75–84, with a median age of 73 years, meaning that the rising life expectancy of the older population itself is increasing the number of BC cases, turning them into a bigger problem for the healthcare [<xref ref-type="bibr" rid="B2-genes-08-00339">2</xref>]. BC is more frequently diagnosed in men than in women and its five-year survival rate, based on data from “Surveillance, Epidemiology, and End Results Program” (SEER), is estimated at 77.3% [<xref ref-type="bibr" rid="B1-genes-08-00339">1</xref>]. BC is the ninth leading cause of cancer death in the USA with 4.4 deaths per 100,000 men and women per year (time frame: 2010–2014), according to SEER data.</p>
</sec>
<sec id="sec2-genes-08-00339">
<title>2. Classification and Etiology of BC</title>
<p>There are two main types of BC, according to its histopathology: about 90% of them begin in the urothelium (the transitional epithelium that lines much of the urinary tract including the renal pelvis, the ureters, the bladder and parts of the urethra) and are classified as transitional cell carcinoma or urothelial cell carcinoma; additionally, approximately 5% of BC are squamous cell carcinoma and less than 2% are adenocarcinoma [<xref ref-type="bibr" rid="B3-genes-08-00339">3</xref>]. BC can also be classified considering its invasion of the <italic>muscularis propria</italic> in the bladder wall: at the time of diagnosis, 75–80% cases of BC are classified as non-muscle-invasive bladder cancer (NMIBC), consisting of the pathologic stages Ta (papillary), T1 (invading into the <italic>lamina propria</italic>), and carcinoma in situ (CIS) [<xref ref-type="bibr" rid="B4-genes-08-00339">4</xref>]. The remaining cases are characterized by a variable grade of infiltration of the bladder wall and are known as muscle-invading BC (MIBC), which are a more serious condition: in fact, while patients with NMIBC can often be safely managed with transurethral resection of the tumor (with or without intravesical chemotherapy or immunotherapy), neoadjuvant chemotherapy followed by radical cystectomy (RC) with bilateral pelvic lymph-node dissection (PLND) is the standard of care for patients with MIBC [<xref ref-type="bibr" rid="B5-genes-08-00339">5</xref>].</p>
<p>Many studies focused on possible etiologies of BC, demonstrating that both genetic and epigenetic pathways are correlated with the development of this disease, and that BC is also strongly influenced by environmental factors [<xref ref-type="bibr" rid="B6-genes-08-00339">6</xref>]. In past studies, BC was commonly linked to two main genetic pathways, one involving <italic>FGFR</italic>3 (fibroblast growth factor receptor 3,) mutations, often associated with low-grade tumors and favorable prognosis, and one characterized by <italic>TP53</italic> (tumor protein P53) mutations, mainly identified in advanced tumors with poor prognosis [<xref ref-type="bibr" rid="B7-genes-08-00339">7</xref>]. Currently, numerous other genetic causes have been discovered, concerning several categories of oncogenes and tumor suppressor genes whose altered activities promote carcinogenesis: (i) genes controlling apoptosis [<xref ref-type="bibr" rid="B8-genes-08-00339">8</xref>] such as <italic>Caspase-3</italic> [<xref ref-type="bibr" rid="B9-genes-08-00339">9</xref>], <italic>FAS</italic> (Fas cell surface death receptor) [<xref ref-type="bibr" rid="B10-genes-08-00339">10</xref>], <italic>BCL-2</italic> (B-Cell CLL/Lymphoma 2) [<xref ref-type="bibr" rid="B11-genes-08-00339">11</xref>] and <italic>Survivin</italic> [<xref ref-type="bibr" rid="B12-genes-08-00339">12</xref>]; (ii) genes controlling angiogenesis such as vascular endothelial growth factors (VEGFs) [<xref ref-type="bibr" rid="B13-genes-08-00339">13</xref>], basic fibroblast growth factor and thrombospondin 1 [<xref ref-type="bibr" rid="B14-genes-08-00339">14</xref>]; and (iii) genes controlling signaling and cell–cell interactions as uroplakins [<xref ref-type="bibr" rid="B15-genes-08-00339">15</xref>] and <italic>RAS</italic> (Rat sarcoma viral oncogene homolog) [<xref ref-type="bibr" rid="B16-genes-08-00339">16</xref>]. Many genes involved in other cellular functions seem to play a role in BC development [<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>] and, for this reason, it may be useful to analyze as many of them as possible to define prognosis and treatments.</p>
<p>Among the most important risk factors, there are cigarette smoking, occupational exposures (especially to aromatic amines), water arsenic, <italic>Schistosoma haematobium</italic> infestation, and external beam radiation therapy (EBRT) for urogenital malignancies, which increases the rate of secondary bladder malignancies [<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B18-genes-08-00339">18</xref>]. Cigarette smokers have approximately threefold higher hazard of urinary tract cancer than non-smokers [<xref ref-type="bibr" rid="B19-genes-08-00339">19</xref>]. It has been discovered that cigarette smoke extract exposure induces morphological changes of human BC T24 cells, with enhanced cell migration and invasion, reduced epithelial marker expression and increased mesenchymal marker expression, resulting in the activation of the ERK1/2 (Extracellular Signal-regulated Kinase 1 and 2) pathway as well as of the activator protein 1 (AP-1) [<xref ref-type="bibr" rid="B20-genes-08-00339">20</xref>]. About 20% of BC cases is occupationally related, a much larger percentage compared to other types of cancer which have, in some cases, a work-dependent etiology (4%) [<xref ref-type="bibr" rid="B21-genes-08-00339">21</xref>]. Workers in leather tanneries have a higher hazard to develop BC, likely because of their exposure to chemicals contained in the leather dust [<xref ref-type="bibr" rid="B22-genes-08-00339">22</xref>]. Evidence of higher BC risk was also shown in dye workers, rubber workers, painters, truck drivers and aluminum workers [<xref ref-type="bibr" rid="B23-genes-08-00339">23</xref>]. Many studies focused on the personal use of hair dyes, which contain several chemicals: <italic>p</italic>-phenylenediamine and aminophenyl, for example, have been suggested as possible carcinogens or mutagens. These molecules, when used over a long period of time and in the presence of specific genetic polymorphisms, may increase BC risk [<xref ref-type="bibr" rid="B24-genes-08-00339">24</xref>], sometimes up to 22–50% vs. non-use [<xref ref-type="bibr" rid="B25-genes-08-00339">25</xref>]. It has been established the fundamental role that aromatic amines, such as 2-naphthylamine, 4-aminobiphenyl and benzidine, play as occupational risk factors associated with BC [<xref ref-type="bibr" rid="B26-genes-08-00339">26</xref>]. Another important hazard is the exposure to arsenic in drinking water: an arsenic concentration of 10 μg/liter may increase by 40–100% the risk of bladder and kidney cancers [<xref ref-type="bibr" rid="B27-genes-08-00339">27</xref>]. There are also some world regions in which BC is linked to environmental factors that almost make it an endemic disease: for example, in the Middle East and parts of Africa (especially Egypt), carcinomas of the urinary tract are the most common malignancies, due to <italic>S. haematobium</italic> infections [<xref ref-type="bibr" rid="B28-genes-08-00339">28</xref>].</p>
</sec>
<sec id="sec3-genes-08-00339">
<title>3. Epigenetics and BC</title>
<p>Many scholars have been asked about the meaning of the term ‘epigenetic’: hence different definitions and points of view emerged. Overall, ‘epigenetics’ includes all the biochemical processes that alter gene activity without changing the DNA sequence and that may lead to inheritable modifications [<xref ref-type="bibr" rid="B29-genes-08-00339">29</xref>]. Therefore, epigenetic changes can alter the way a cell interacts with its genetic information, without altering the DNA sequence, at the physiological level.</p>
<p>The hunt for gene variants or mutations that can explain the personal susceptibility to diseases, from autism to cancer to Alzheimer’s disease, has been mostly inconclusive. For this reason, epigenetics may be the key to find a more complete pathogenetic explanation for diseases that do not have clear-cut genetic causes [<xref ref-type="bibr" rid="B30-genes-08-00339">30</xref>]. There are many biochemical processes, which determine epigenetic changes. However, most studies focused on two of them: DNA methylation and histone modifications [<xref ref-type="bibr" rid="B31-genes-08-00339">31</xref>]. DNA methylation (the addition or removal of a methyl group) has been the focus of much research ranging from a developmental and imprinting perspective to its contribution to diseases such as cancer [<xref ref-type="bibr" rid="B32-genes-08-00339">32</xref>]. Aberrant histone modifications, or the dysregulated activity of the enzymes that catalyze these modifications, may affect the genome integrity and chromosome segregation, leading to the possible development of many maladies, including cancer [<xref ref-type="bibr" rid="B33-genes-08-00339">33</xref>]. Even though these phenomena have been known for decades, studies investigating the impact of epigenetic changes on human diseases have only recently intensified.</p>
<p>Remarkably, epigenetic changes mediated by non-coding RNAs (ncRNA) are of extreme importance for understanding the neoplastic transformation of the urothelium. Indeed, there is not only a direct relationship between activity and mutations of these molecules, intended as members of a complex epigenetic system [<xref ref-type="bibr" rid="B34-genes-08-00339">34</xref>], and BC formation [<xref ref-type="bibr" rid="B35-genes-08-00339">35</xref>], but also a known association between some chemicals and changes of ncRNA structures [<xref ref-type="bibr" rid="B36-genes-08-00339">36</xref>]. In particular, benzo(a)pyrene (produced during coal gasification, aluminum smelting and tobacco smoking, in all cases as a result of incomplete combustion), 2-nitrofluorene (a by-product of combustion) and 4-nitrosomorpholine (a contaminant in rubber products) can potentially impair the function of some ncRNA and, probably, induce BC [<xref ref-type="bibr" rid="B37-genes-08-00339">37</xref>].</p>
</sec>
<sec id="sec4-genes-08-00339">
<title>4. Non-Coding RNAs: An Overview</title>
<p>Modern studies and technologies allowed pointing out that only a small portion (about 10–15%) of the mammalian genome is functional [<xref ref-type="bibr" rid="B38-genes-08-00339">38</xref>], and only 3% consists of protein-coding genes [<xref ref-type="bibr" rid="B39-genes-08-00339">39</xref>]. The greatest part of the human genome, which does not encode for proteins, is known as ‘non-coding DNA’: in fact, it does not lead to the biosynthesis of specific proteins. However, additional studies have demonstrated that non-coding DNA holds a very important role in many other biochemical processes. Indeed, it carries the information that is required to synthesize specific RNA molecules, which are not translated into proteins (ncRNA). Among others, transfer RNAs (tRNA) and ribosomal RNAs (rRNA) represent the most abundant ncRNA molecules, confirming the central role played by this huge part of the human genome. ncRNA, other than rRNA and tRNA, are usually categorized based on their length: there are long non-coding RNAs (lncRNA), which are longer than 200 nucleotides [<xref ref-type="bibr" rid="B40-genes-08-00339">40</xref>] and small non-coding RNA, which are usually 20–25 nucleotides long and are further subdivided according to their function and/or role (<xref ref-type="table" rid="genes-08-00339-t001">Table 1</xref> and References therein).</p>
<p>Over the years, many roles have been attributed to ncRNA. It has been proposed that ncRNA play a crucial role in maintaining genomic stability, which is essential for cell survival and prevent tumorigenesis [<xref ref-type="bibr" rid="B51-genes-08-00339">51</xref>], by finely tuning DNA expression [<xref ref-type="bibr" rid="B52-genes-08-00339">52</xref>] and forming complexes with other molecules (lncRNA, microRNA (miR) and proteins) to maintain the physiologic homeostasis [<xref ref-type="bibr" rid="B53-genes-08-00339">53</xref>].</p>
</sec>
<sec id="sec5-genes-08-00339">
<title>5. Long Non-Coding RNA</title>
<p>Long Non-coding RNA are involved in many important biochemical processes such as the major pathways of cell growth, proliferation, differentiation and survival. Consequently, they are considered essential regulators of the genetic information and for this reason, in the last years, several studies focused on their activities. Their deregulation can promote tumor formation, progression and metastasis in bladder tissues, showing that they play a crucial role in the carcinogenesis of the urothelium [<xref ref-type="bibr" rid="B54-genes-08-00339">54</xref>]. lncRNA can sustain proliferative signaling, allow evading growth suppression, promote apoptosis resistance, support replicative immortality, activate invasion and metastasis, and induce angiogenesis [<xref ref-type="bibr" rid="B55-genes-08-00339">55</xref>]. These findings are a great step forward for understanding cellular pathways and defining the prognosis of a large variety of tumors; indeed, many studies aim to translate this evidence into actionable clinical steps, for example using specific lncRNA as biomarkers or therapeutic targets [<xref ref-type="bibr" rid="B41-genes-08-00339">41</xref>]. Transcribed ultraconserved region (T-UCR) RNAs are a specific class of lncRNA possibly involved in tumorigenesis; notably, one out of the approximately 480 T-UCR identified so far has a recognized role in BC formation [<xref ref-type="bibr" rid="B56-genes-08-00339">56</xref>]. The lncRNA that we have collected (<xref ref-type="table" rid="genes-08-00339-t002">Table 2</xref>) and commented have been described as having a role in BC and were retrieved from PubMed and the database ‘Lnc2Cancer’ available at <uri xlink:href="http://www.bio-bigdata.com/lnc2cancer/home.jsp">http://www.bio-bigdata.com/lnc2cancer/home.jsp</uri> [<xref ref-type="bibr" rid="B57-genes-08-00339">57</xref>]. Their role as oncogenes or tumor suppressor is summarized in <xref ref-type="fig" rid="genes-08-00339-f001">Figure 1</xref>A.</p>
<sec id="sec5dot1-genes-08-00339">
<title>5.1. UCA1</title>
<p>Urothelial cancer-associated 1 (UCA1) is encoded in a locus that maps on chromosome 19p13.12 and is 1413 bases long [<xref ref-type="bibr" rid="B60-genes-08-00339">60</xref>]. It belongs to the family of oncogenic lncRNA involved in BC progression because of its role in cell cycle regulation. It is believed to promote BC indirectly acting on the PI3K-AKT (phosphatidylinositide 3-kinase—Ak thymoma) pathway through the CREB (cAMP response element-binding protein) protein deregulation [<xref ref-type="bibr" rid="B60-genes-08-00339">60</xref>]. Under hypoxic conditions, the upregulation of UCA1 promotes cell proliferation, migration, and invasion; furthermore, it inhibits apoptosis [<xref ref-type="bibr" rid="B61-genes-08-00339">61</xref>]. It has been shown that in ovarian cancer UCA1 interacts with the microRNA miR485-5p, inhibiting its function [<xref ref-type="bibr" rid="B62-genes-08-00339">62</xref>]. In this system, the knockdown of UCA1 or the overexpression of miR485-5p reduce mRNA and protein levels of the target matrix metalloprotease MMP14, which is involved in pathologic invasion and metastasis. A similar pathway has been demonstrated in BC as well, in an article showing that miR485-5p is a tumor suppressor [<xref ref-type="bibr" rid="B63-genes-08-00339">63</xref>]. Further studies are needed to verify that UCA1 and miR485-5p interact also in the bladder. Several studies have investigated the reliability of the UCA1 presence in the urine as a biomarker for urothelial cancer, demonstrating its great diagnostic value in BC (specificity: 91.8%; sensitivity: 80.9%) [<xref ref-type="bibr" rid="B64-genes-08-00339">64</xref>,<xref ref-type="bibr" rid="B65-genes-08-00339">65</xref>]; however, its role in the follow-up of recurring tumors remains limited [<xref ref-type="bibr" rid="B66-genes-08-00339">66</xref>]. Moreover, growing subsequent evidence suggests that the aberrant overexpression of UCA1 is associated with high risk of poor outcome or clinicopathological features in several types of cancer, including BC [<xref ref-type="bibr" rid="B67-genes-08-00339">67</xref>]. UCA1 activity is strictly related to aggressive BC phenotypes; in fact, UCA1 can promote the transdifferentiation of epithelial cells into motile mesenchymal cells, a process known as epithelial–mesenchymal transition (EMT) [<xref ref-type="bibr" rid="B68-genes-08-00339">68</xref>]. This feature can be explained by the effect that UCA1 produces through the hsa-miR-145–ZEB1/2–FSCN1 (<italic>Homo sapiens</italic> miR-145—Zinc Finger E-box binding homeobox 1 and 2—fascin actin-bundling protein 1) pathway. It has been demonstrated that hsa-miR-145 inhibits BC cell migration and invasion [<xref ref-type="bibr" rid="B69-genes-08-00339">69</xref>]; consequently, the overexpression of UCA1 is linked to marked repression of hsa-miR-145, and vice versa, resulting in a stimulus that may make cancer more aggressive. In addition, UCA1 induces EMT and increases the migratory and invasive abilities of BC cells also by upregulating the expression levels of the zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2) [<xref ref-type="bibr" rid="B70-genes-08-00339">70</xref>].</p>
</sec>
<sec id="sec5dot2-genes-08-00339">
<title>5.2. MALAT1</title>
<p>Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also known as nuclear-enriched abundant transcript 2 (NEAT2), is encoded in a locus that maps on chromosome 11q13.1 and its length is around 7 Kb [<xref ref-type="bibr" rid="B71-genes-08-00339">71</xref>]. Interestingly, the 3′ end of the main transcript contains a conserved tRNA-like sequence that is cleaved off and processed to generate a short tRNA-like ncRNA called mascRNA (MALAT1-associated small cytoplasmic RNA; 61nt long); consequently, the post-transcriptional processing of MALAT1 produces two ncRNAs from a single, original transcript [<xref ref-type="bibr" rid="B72-genes-08-00339">72</xref>]. Both transcripts are widely expressed in all human tissues analyzed so far. MALAT1 is often associated with multiple physiological processes, such as alternative splicing, nuclear organization, and epigenetic modulation of gene expression. However, this lncRNA is also involved in pathological processes, ranging from diabetes complications to different types of cancer [<xref ref-type="bibr" rid="B73-genes-08-00339">73</xref>]. The role of MALAT1 in tumorigenesis has been deeply investigated; its overexpression has been associated with the promotion of malignancy, while its knockdown is linked to the inhibition of cell proliferation and invasion in different cancer types [<xref ref-type="bibr" rid="B74-genes-08-00339">74</xref>]. However, the implications of MALAT1 in carcinogenesis have not yet been fully clarified because of the controversial results that emerged from numerous studies. The overexpression of MALAT1 is generally associated with poor prognosis in patients with various types of cancer, even though the mechanisms underlying this relationship remain unclear [<xref ref-type="bibr" rid="B75-genes-08-00339">75</xref>]. The upregulation of MALAT1 promotes cell migration in BC by inducing EMT; its downregulation results in a decrease of this process [<xref ref-type="bibr" rid="B76-genes-08-00339">76</xref>]. These findings suggest an important role for MALAT1 in regulating metastasis in BC patients and its possible therapeutic use as a target molecule. Since cancer patients expressing high levels of this lncRNA have a poorer clinical outcome, MALAT1 can be considered a potential prognostic biomarker for various cancers, including BC [<xref ref-type="bibr" rid="B77-genes-08-00339">77</xref>].</p>
</sec>
<sec id="sec5dot3-genes-08-00339">
<title>5.3. H19</title>
<p><italic>H19</italic> is a locus mapping on chromosome 11p15.5 (inside a genomic region that is approximately 6 Kb long), which encodes for a lncRNA and is also known as ASM (because of its expression in rats’ Adult Skeletal Muscle) or BWS (since its aberrant expression can be involved in the Beckwith-Wiedemann syndrome). H19 is an imprinted transcript, expressed exclusively from the maternal allele, and is only found in mammalian genomes [<xref ref-type="bibr" rid="B78-genes-08-00339">78</xref>]. It is expressed during fetal development, in particular in mesoderm- and endoderm-derived tissues [<xref ref-type="bibr" rid="B79-genes-08-00339">79</xref>], and its expression ends at birth; in adults, it is found almost exclusively in a number of cancers, including BC [<xref ref-type="bibr" rid="B80-genes-08-00339">80</xref>,<xref ref-type="bibr" rid="B81-genes-08-00339">81</xref>]. As for the bladder, Ariel et al. demonstrated that H19 is abundantly expressed in the fetal bladder mucosa and in the carcinoma of the urinary bladder [<xref ref-type="bibr" rid="B82-genes-08-00339">82</xref>]. H19 is a potent oncogene: its aberrant expression is associated with BC tumorigenesis, metastasis, and poor prognosis, since it is one of the most upregulated lncRNA in cancerous cells compared with adjacent noncancerous tissue [<xref ref-type="bibr" rid="B83-genes-08-00339">83</xref>]. The search for H19-positive urinary cells has become a highly sensitive screening test for urothelial cancer; in fact, H19 has been detected in the urine of 90.5% of patients and only in 25.9% of controls [<xref ref-type="bibr" rid="B84-genes-08-00339">84</xref>]. The molecular organization and mechanisms of action of this ncRNA are quite complex and not fully understood. The primary transcript of <italic>H19</italic> also acts as the primary transcript for miR-675, a 23nt long microRNA harbored between nucleotides 1014 and 1036 of the main transcript [<xref ref-type="bibr" rid="B85-genes-08-00339">85</xref>]. In addition, the H19/IGF2-imprinting control region, which is located just upstream of <italic>H19</italic>, coordinates the expression of both <italic>H19</italic> and <italic>IGF2</italic> (insulin like growth factor 2), the latter being expressed exclusively from the paternal allele [<xref ref-type="bibr" rid="B86-genes-08-00339">86</xref>]. <italic>H19</italic> knockout causes loss of <italic>IGF2</italic> imprinting, suggesting a control mechanism at the transcriptional level [<xref ref-type="bibr" rid="B87-genes-08-00339">87</xref>,<xref ref-type="bibr" rid="B88-genes-08-00339">88</xref>]; in addition, both sense and antisense transcripts from the <italic>H19</italic> locus bind the PRC2 (polycomb repressive complex 2) chromatin modification complex in mouse embryonic stem cells [<xref ref-type="bibr" rid="B89-genes-08-00339">89</xref>]. However, H19 also binds the IGF2 mRNA binding-protein (IMP) family members that, in turn, regulate IGF2 translation, thus suggesting for H19 also a post-transcriptional regulation of target genes [<xref ref-type="bibr" rid="B90-genes-08-00339">90</xref>]. One of the pathological mechanisms involved in the H19 activity is linked to the expression of miR-675: notably, miR-675 levels were remarkably increased in BC tissues, where this miR is able to inhibit the activation of the tumor suppressor TP53, resulting in the abnormal proliferation of BC cells and increased cancer growth [<xref ref-type="bibr" rid="B91-genes-08-00339">91</xref>]. miR-675 also downregulates the tumor suppressor retinoblastoma (RB) protein in human colorectal cancer [<xref ref-type="bibr" rid="B92-genes-08-00339">92</xref>]. However, it is likely that H19 has also functions that are independent of miR-675, since it harbors secondary structures that are widely conserved and may act as a stable docking platform for a regulatory ribonucleoprotein (RNP) composed of the 3′ half of the H19 transcript and of up to four IMP1 molecules [<xref ref-type="bibr" rid="B93-genes-08-00339">93</xref>].</p>
</sec>
<sec id="sec5dot4-genes-08-00339">
<title>5.4. TUG1</title>
<p>Taurine Upregulated Gene 1 (<italic>TUG1</italic>) maps on chromosome 22q12.2, in a locus of approximately 10 Kb. Three splice variants of <italic>TUG1</italic> were identified in mouse, while in man there are four possible splice variants, whose cDNA lengths are 3.3, 5.9, 6.4, and 9.7 kb, respectively [<xref ref-type="bibr" rid="B94-genes-08-00339">94</xref>]. Human TUG1 is ubiquitously expressed in tissues and cells and localizes in nuclear and cytoplasmic foci in human fetal foot fibroblasts [<xref ref-type="bibr" rid="B95-genes-08-00339">95</xref>]. TUG1 is another lncRNA whose aberrant overexpression is commonly linked to urothelial carcinoma of the bladder, as well as to B-cell malignancies, esophageal squamous cell carcinoma, hepatocellular carcinoma and osteosarcoma [<xref ref-type="bibr" rid="B96-genes-08-00339">96</xref>]. TUG1 knockdown suppresses proliferation and promotes apoptosis of BC cells, by inhibiting the activation of the Wnt/β-catenin (wingless-type MMTV integration site/beta-catenin) pathway and by affecting Zinc finger E-box-binding homeobox 2 (ZEB2) expression [<xref ref-type="bibr" rid="B97-genes-08-00339">97</xref>]. A research demonstrated the oncogenic role and association with worse overall survival of this lncRNA, especially in high-grade muscle-invasive BC: in this study, TUG1 silencing in vitro led to 34% decrease in cancer cell proliferation and 23% reduction in the migration capacity of cancer cells [<xref ref-type="bibr" rid="B98-genes-08-00339">98</xref>]. The role of TUG1 in high-grade BC may be related to its interaction with TP53, a well-known marker of these tumors [<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]. Indeed, <italic>TUG1</italic> expression is induced by TP53 in response to DNA damage [<xref ref-type="bibr" rid="B99-genes-08-00339">99</xref>], and the artificial depletion of TUG1 via small interfering RNA (siRNA) results in the upregulation of genes involved in cell cycle regulation in both fetal lung and foot fibroblasts [<xref ref-type="bibr" rid="B95-genes-08-00339">95</xref>]. Further studies are needed to better understand the importance of TUG1, though its potential roles as biomarker and therapeutic target in bladder urothelial carcinoma seem to be well established.</p>
</sec>
<sec id="sec5dot5-genes-08-00339">
<title>5.5. MEG3</title>
<p>There are also cases in which the reduced expression of a certain lncRNA can lead to several pathologies, and cancer is one of them. One example is represented by Maternally Expressed Gene 3 (MEG3) lncRNA, whose cytogenetic band is 14q32.2 (a site that putatively contains a tumor suppressor gene involved in the pathogenesis of meningiomas) and which has a complex organization, being ca. 1.6 kb long in humans with a number of splice isoforms and evidence of retained introns that create longer transcripts [<xref ref-type="bibr" rid="B100-genes-08-00339">100</xref>]. In addition, in this case, there is an example of an imprinted, maternally expressed locus [<xref ref-type="bibr" rid="B101-genes-08-00339">101</xref>] that is part of a larger cluster of imprinted genes, named <italic>DLK1-DIO3</italic> (delta like non-canonical notch ligand 1—iodothyronine deiodinase 3); like the <italic>IGF2/H19</italic> domain, the <italic>MEG3/GTL2/DLK1</italic> locus has areas of differential methylation-hypermethylation on the paternal and hypomethylation on the maternal allele [<xref ref-type="bibr" rid="B102-genes-08-00339">102</xref>]. <italic>MEG3</italic> expression is highly regulated temporally and spatially in mouse as well as in man. In humans, it is expressed in the adult brain [<xref ref-type="bibr" rid="B103-genes-08-00339">103</xref>] and normal pituitary gland (but not in pituitary adenomas) [<xref ref-type="bibr" rid="B104-genes-08-00339">104</xref>]; it is upregulated in the <italic>nucleus accumbens</italic> of heroin abusers [<xref ref-type="bibr" rid="B105-genes-08-00339">105</xref>] and downregulated in the caudate nucleus of Huntington’s disease patients [<xref ref-type="bibr" rid="B106-genes-08-00339">106</xref>]. MEG3 localization may be either nuclear or cytoplasmic; when it is nuclear, it has been found associated with chromatin [<xref ref-type="bibr" rid="B107-genes-08-00339">107</xref>]. The downregulation of <italic>MEG3</italic> is commonly associated with the progression of different types of cancer; in fact, MEG3 has the strong ability to inhibit the proliferation of several malignant human carcinoma cell lines [<xref ref-type="bibr" rid="B104-genes-08-00339">104</xref>]. It has been demonstrated that this anti-oncogene contributes to the activation of <italic>TP53</italic>, one of the most important tumor suppressor genes, probably through secondary structural motifs [<xref ref-type="bibr" rid="B108-genes-08-00339">108</xref>]. Furthermore, MEG3 is able to inhibit cell proliferation even in the absence of TP53 [<xref ref-type="bibr" rid="B109-genes-08-00339">109</xref>]; in addition, it can also control gene expression at imprinted loci through the recruitment of the PRC2 complex [<xref ref-type="bibr" rid="B89-genes-08-00339">89</xref>]. Experiments aimed at elucidating its role in cellular growth further demonstrated that its ectopic expression inhibits growth and stimulates <italic>TP53</italic> expression [<xref ref-type="bibr" rid="B108-genes-08-00339">108</xref>]. On the other hand, <italic>MEG3</italic> knock-out promotes the expression of VEGF (vascular endothelial growth factor) signaling pathway genes in the brain, suggesting that MEG3 function as tumor suppressor may in part be due to angiogenesis inhibition [<xref ref-type="bibr" rid="B110-genes-08-00339">110</xref>]. As in other tissues, also in BC MEG3 levels are lower than normal controls. This lncRNA is able to suppress autophagy activation, while downregulated MEG3 activates autophagy and increases cell proliferation in BC cell lines [<xref ref-type="bibr" rid="B111-genes-08-00339">111</xref>]. The downregulation of <italic>MEG3</italic> is based on the epigenetic silencing of the 14q32 imprinted gene cluster [<xref ref-type="bibr" rid="B112-genes-08-00339">112</xref>]. All biochemical processes in which MEG3 is involved make it an excellent marker for BC prognosis: circulating MEG3 status in tumors may be useful also for selecting patients who are most likely to benefit from adjuvant therapy, which is used to reduce the risk of cancer recurrence [<xref ref-type="bibr" rid="B113-genes-08-00339">113</xref>].</p>
</sec>
<sec id="sec5dot6-genes-08-00339">
<title>5.6. MIR31HG</title>
<p>MIR31HG (also known as LOC554202) is another example of lncRNA whose inactivation promotes the progression of BC, as well as of other types of cancer. <italic>MIR31HG</italic> maps on chromosome 9p21.3 [<xref ref-type="bibr" rid="B114-genes-08-00339">114</xref>] and its locus spans more than 106 kb, although the final transcript is only 2246 bp long; exon 1 contains a CpG island, and intron 1 harbors miR31 [<xref ref-type="bibr" rid="B115-genes-08-00339">115</xref>]. Interestingly, the regulation of this lncRNA depends on the cancer type. The CpG island is responsible for gene expression control through DNA methylation in triple-negative breast cancer (TNBC) cell lines [<xref ref-type="bibr" rid="B115-genes-08-00339">115</xref>]. It has also been shown that MIR31HG is upregulated in breast cancer tissues compared with normal tissues and that higher MIR31HG expression positively correlates with tumor size and staging. On the contrary, its knockdown via siRNA reduces proliferation, migration, and invasion in breast cancer cell lines, with accumulation of cells in the G0/G1 phase and loss of cells in S phase, and at the same time increases apoptosis [<xref ref-type="bibr" rid="B114-genes-08-00339">114</xref>]. The relationship between decreased expression of MIR31HG and development of BC suggests its role as tumor-suppressor in bladder, and its expression levels in BC patients are negatively correlated with advanced TNM (tumor-node-metastasis) stage [<xref ref-type="bibr" rid="B116-genes-08-00339">116</xref>]. Thus, MIR31HG is a new candidate biomarker for patients with BC, although the molecular mechanism by which it is regulated in the bladder has still to be elucidated.</p>
</sec>
<sec id="sec5dot7-genes-08-00339">
<title>5.7. Linc-UBC1</title>
<p>Long intergenic non-coding RNA upregulated in bladder cancer 1 (linc-UBC1, approved by Human Genome Organization (HUGO) Gene Nomenclature Committee (HGNC) symbol: BLACAT1) is a lncRNA that is overexpressed in BC and was found to be over-expressed in about 60% of invasive BC tissue specimens; it was correlated with lymph node metastasis and poor survival [<xref ref-type="bibr" rid="B117-genes-08-00339">117</xref>]. The gene maps at position 1q32.1 in a locus longer than 20 Kb, but its final transcript is only 3 Kb long (a single exon); this transcript localizes mainly inside the nucleus [<xref ref-type="bibr" rid="B117-genes-08-00339">117</xref>]. RNA immunoprecipitation experiments revealed that linc-UBC1 interacts with two components of the PRC2 complex; thus, this RNA probably functions, at least partially, by modulating the histone methylation and chromatin structure, and consequently influencing gene expression [<xref ref-type="bibr" rid="B117-genes-08-00339">117</xref>].</p>
</sec>
<sec id="sec5dot8-genes-08-00339">
<title>5.8. LOC572558</title>
<p>LOC572558 (cytogenetic band of its gene: 9q13) has been recently identified in BC specimens [<xref ref-type="bibr" rid="B118-genes-08-00339">118</xref>] and is one of the most deregulated lncRNA in BC; it can be considered an important tumor suppressor, which regulates the p53 signaling pathway in BC by dephosphorylating AKT and MDM2 (mouse double minute 2 homolog) and phosphorylating TP53 protein. Available data show that it is able to inhibit cell proliferation and motility; in fact, it can induce S phase arrest of the cell cycle and promote apoptosis [<xref ref-type="bibr" rid="B119-genes-08-00339">119</xref>].</p>
</sec>
<sec id="sec5dot9-genes-08-00339">
<title>5.9. PANDAR</title>
<p>Promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR) is a lncRNA that regulates the expression of genes involved in the apoptotic response to DNA damage [<xref ref-type="bibr" rid="B120-genes-08-00339">120</xref>]; the coding gene maps at position 6p21.2 and its transcript is approximately 1.5 Kb long. PANDAR is significantly upregulated in BC tissues, compared with adjacent non-tumoral tissues; moreover, its high levels were correlated with higher histological grade and advanced TNM stage. It was shown that, after silencing PANDAR, cell proliferation and migration are inhibited, while apoptosis is induced [<xref ref-type="bibr" rid="B121-genes-08-00339">121</xref>]. Hung et al. suggested that the DNA damage induces TP53-mediated transcription at the locus containing both CDKN1A and PANDAR; this transcription mediates cell cycle arrest and inhibits NFYA (nuclear transcription factor Y subunit alpha, a transcription factor involved in the activation of pro-apoptotic genes) [<xref ref-type="bibr" rid="B120-genes-08-00339">120</xref>]. A recent report also shows the role of PANDAR in the stabilization of TP53 protein without influencing the TP53 mRNA stability [<xref ref-type="bibr" rid="B122-genes-08-00339">122</xref>].</p>
</sec>
<sec id="sec5dot10-genes-08-00339">
<title>5.10. GHET1</title>
<p>Gastric carcinoma high expressed transcript 1 (GHET1), is a recently identified lncRNA, originally isolated in patients affected by gastric carcinoma, where it is upregulated; the high expression levels of this RNA are directly correlated with tumor size, tumor invasion and poor survival [<xref ref-type="bibr" rid="B123-genes-08-00339">123</xref>]. The gene location is 7q36.1. GHET1 is upregulated in BC as well [<xref ref-type="bibr" rid="B124-genes-08-00339">124</xref>]; indeed, Li et al. showed its involvement in the proliferation and invasion of BC cells in vitro and in the EMT of BC cell lines, and that its upregulation is directly related with tumor status and size, but not with other variables such as age or gender. They conclude that GHET1 contributes to the tumor progression and may be used as a novel diagnostic BC marker.</p>
</sec>
<sec id="sec5dot11-genes-08-00339">
<title>5.11. ncRAN</title>
<p>Another recently discovered, upregulated lncRNA involved in BC formation is ncRAN (non-coding RNA expressed in aggressive neuroblastoma) [<xref ref-type="bibr" rid="B125-genes-08-00339">125</xref>], a long ncRNA originally isolated in patients affected by aggressive neuroblastoma [<xref ref-type="bibr" rid="B126-genes-08-00339">126</xref>]; its gene maps at position 17q25.1 and has two similarly sized transcripts, whose lengths are 2.1 and 2.2 Kb, respectively. Both ncRAN transcripts are significantly more expressed in invasive bladder tumor cell lines than in superficial tumor cell lines, where they promote cell proliferation, migration, and invasion [<xref ref-type="bibr" rid="B125-genes-08-00339">125</xref>]. It is currently unknown if the two isoforms differ in some way with respect to cancer, including BC cases. Similarly, the targets of ncRAN are currently unknown. Therefore, ncRAN, despite being a promising BC biomarker, is still considered only a ‘potential’ oncogene and further research is needed to clarify its biological role [<xref ref-type="bibr" rid="B125-genes-08-00339">125</xref>].</p>
</sec>
<sec id="sec5dot12-genes-08-00339">
<title>5.12. GAS5</title>
<p>Growth arrest specific 5 (<italic>GAS5</italic>) is a gene mapping at position 1q25.1. The <italic>GAS5</italic> primary transcript (technically, a lncRNA) contains 12 exons in both man and mouse. However, these exons are poorly conserved, and the specific search of putative polypeptides derived by alternative splicing has been so far inconclusive [<xref ref-type="bibr" rid="B127-genes-08-00339">127</xref>,<xref ref-type="bibr" rid="B128-genes-08-00339">128</xref>]. Instead, its introns are highly conserved, and their analysis, comparing human and mouse <italic>GAS5</italic> sequences, revealed that they contain several small nucleolar RNA (snoRNA) (that are small non-coding RNAs (sncRNA)) in the same number and order, i.e., 11 introns containing nine conserved snoRNA arranged in the same way [<xref ref-type="bibr" rid="B127-genes-08-00339">127</xref>]. In 2013, Liu et al. demonstrated that, in most BC samples, <italic>GAS5</italic> transcription is significantly downregulated [<xref ref-type="bibr" rid="B129-genes-08-00339">129</xref>], as in breast cancer [<xref ref-type="bibr" rid="B130-genes-08-00339">130</xref>], allowing classifying this gene as a tumor suppressor. Instead, <italic>GAS5</italic> overexpression in proliferating cells is sufficient to stop the cell division [<xref ref-type="bibr" rid="B129-genes-08-00339">129</xref>]. Interestingly, in the same paper it is reported that Cyclin-dependent kinase 6 (CDK6) is specifically associated with GAS5, thus permitting assigning this transcript to at least one target gene and a specific role in the BC formation.</p>
</sec>
<sec id="sec5dot13-genes-08-00339">
<title>5.13. ANRIL</title>
<p>Antisense non-coding RNA in the INK4 locus (ANRIL) is encoded by a gene that maps on chromosome 9p21.3; two splicing forms are known, of 2.7 and 3.8 Kb. It was originally discovered by searching EST (expressed sequence tag) databases in a region of chromosome 9, which is frequently deleted in the melanoma-neural system tumor (NST) syndrome [<xref ref-type="bibr" rid="B131-genes-08-00339">131</xref>]. ANRIL seems to be ubiquitously expressed in human tissues (in 20 tissues examined), at the same level and always together with CDKN2A/INK4/ARF (cyclin-dependent kinase inhibitor 2A—inhibitor of CDK4—alternate reading frame), whose genes map next to that of ANRIL and might be regulated by the same factors [<xref ref-type="bibr" rid="B131-genes-08-00339">131</xref>]. ANRIL is dysregulated in several cancers, including BC; in bladder, it regulates cell proliferation and apoptosis through the intrinsic pathway, since its knockdown corresponds to decreased expression of <italic>BCL-2</italic>, increased expressions of <italic>BAX</italic> (BCL2 Associated X), cytoplasmic <italic>cytochrome c</italic> and <italic>SMAC</italic> (second mitochondria-derived activator of caspases), and cleavage of Caspase-9, Caspase-3 and PARP (poly ADP ribose polymerase) [<xref ref-type="bibr" rid="B132-genes-08-00339">132</xref>].</p>
</sec>
<sec id="sec5dot14-genes-08-00339">
<title>5.14. HIF1A-AS2</title>
<p>Hypoxia inducible factor 1 alpha antisense RNA-2 (HIF1A-AS2) was originally discovered in samples of human renal cancer; its gene maps on chromosome 14q23.2 and, reportedly, produces a AU-rich transcript of 1577 nucleotides [<xref ref-type="bibr" rid="B133-genes-08-00339">133</xref>]. The 3’ 882 nucleotides of HIF1A-AS2 are completely complementary to the 3’-UTR of HIF1A, which is transcribed in the opposite orientation, and indeed its upregulation corresponds to a downregulation of HIF1A in a lymphocyte cell line under hypoxia stress [<xref ref-type="bibr" rid="B133-genes-08-00339">133</xref>]. These results, which are cell line specific, were subsequently further validated upon camptothecin treatment [<xref ref-type="bibr" rid="B134-genes-08-00339">134</xref>,<xref ref-type="bibr" rid="B135-genes-08-00339">135</xref>]. Recently, HIF1A-AS2 upregulation was found also in BC samples, where its expression levels are positively associated with advanced clinical pathologic grade and TNM stage [<xref ref-type="bibr" rid="B136-genes-08-00339">136</xref>].</p>
</sec>
<sec id="sec5dot15-genes-08-00339">
<title>5.15. HOTAIR and HOXD-AS1</title>
<p>HOX (homeobox) transcript antisense RNA (HOTAIR/HOXAS) belongs to a ncRNAs family, identified in human fibroblast, which has roughly 200 HOX [<xref ref-type="bibr" rid="B137-genes-08-00339">137</xref>]. This RNA is transcribed from a locus mapping on chromosome 12q13.13; it was described that the gene encodes a 2158 nt long ncRNA whose function is to provide a modular scaffold for multiple histone modification complexes [<xref ref-type="bibr" rid="B138-genes-08-00339">138</xref>]. Interestingly, its pattern of expression is position-dependent as it happens for the HOX genes, i.e., HOTAIR is more expressed towards the posterior and distal sites in the adult human body [<xref ref-type="bibr" rid="B137-genes-08-00339">137</xref>]. Its depletion through RNA interference causes the upregulation of several HOX genes, as well as several HOX ncRNA, and loss of the histone-3 trimethylation on lys27 over the HOXD locus; the contemporary loss of SUZ12 (suppressor of zeste 12) in the same chromosome domain supports the hypothesis that HOTAIR might regulate the polycomb repressive complex-2 (PRC2) localization and HOXD silencing [<xref ref-type="bibr" rid="B137-genes-08-00339">137</xref>]. Dysregulation of HOTAIR has been linked to several cancer types, including malignancies of the breast and of epithelial types, and is associated with more aggressive tumor behaviors and metastasis formation [<xref ref-type="bibr" rid="B139-genes-08-00339">139</xref>]. Its connection with BC has been demonstrated recently: in particular, its upregulation is a hallmark of recurrence in stage Ta/T1 [<xref ref-type="bibr" rid="B140-genes-08-00339">140</xref>] probably because of its modulation of the cancer epigenome [<xref ref-type="bibr" rid="B141-genes-08-00339">141</xref>]. This possibility is further supported by the fact that HOTAIR contributes to change the balance of histone modification between H3K4me3 and H3K27me3 on the miR-205 promoter, thus causing the silencing of miR-205, which in turn has a role in the inhibition of cell proliferation, migration and invasion by direct targeting of the <italic>cyclin J</italic> (<italic>CCNJ</italic>) gene, a regulator of cell cycle progression [<xref ref-type="bibr" rid="B142-genes-08-00339">142</xref>].</p>
<p>HOXD cluster antisense RNA 1 (HOXD-AS1, also known as HOXD antisense growth-associated long non-coding RNA, HAGLR) belongs to the HOXD cluster on chromosome 2 (at position 2q31.1) and has been recently associated to BC formation and progression; in particular, Li et al. demonstrated that its synthetic tetracycline-controllable shRNA targeting is sufficient to inhibit the progression of BC, although it is unclear how this happens [<xref ref-type="bibr" rid="B143-genes-08-00339">143</xref>].</p>
</sec>
<sec id="sec5dot16-genes-08-00339">
<title>5.16. MDC1-AS1</title>
<p>Mediator of DNA damage checkpoint protein 1 (MDC1) is a regulator of the intra-S phase and G2/M cell cycle checkpoints whose role is recruiting DNA repair proteins to the site of damage. It is involved in determining cell survival fate in association with tumor suppressor protein TP53. Mediator of DNA damage checkpoint protein 1 antisense RNA 1 (MDC1-AS1, encoded at location 6p21.33) is the antisense transcript of the same gene. Xue et al. found that the expression levels of MDC1-AS1 and MDC1 are both downregulated in BC and there is an inhibitory role of this antisense RNA on the malignant cell behavior of EJ and T24 BC cell lines [<xref ref-type="bibr" rid="B144-genes-08-00339">144</xref>]. Interestingly, the same study demonstrated that the over-expression of MDC1-AS1 promotes the upregulation of the MDC1 coding gene both at RNA and protein levels, suggesting that MDC1-AS1 has an inhibitory role on BC cells proliferation through its upregulation of the tumor suppressor gene <italic>MDC1</italic>. While this subject is still under investigation, the easiest explanation found so far is that, in some way, this antisense RNA can stabilize the MDC1 mRNA.</p>
</sec>
<sec id="sec5dot17-genes-08-00339">
<title>5.17. PCAT-1</title>
<p>Prostate Cancer Associated Transcript 1 (PCAT-1) was originally identified as a biomarker of prostate cancer [<xref ref-type="bibr" rid="B145-genes-08-00339">145</xref>], but subsequently it was also found to be involved in the progression of colorectal cancer [<xref ref-type="bibr" rid="B146-genes-08-00339">146</xref>]. This ncRNA transcript has two exons: exon 1 contains a retroviral long terminal repeat (LTR) sequence derived from LTR78B, while exon two contains sequences from the HSMAR1 mariner family transposase that, in turn, internally hosts an AluY repeat element. <italic>PCAT-1</italic> maps in the 8q24 locus, which is frequently amplified in prostate cancer; however, it was shown that PCAT-1 upregulation is not dependent on genomic amplification [<xref ref-type="bibr" rid="B145-genes-08-00339">145</xref>]. PCAT-1 is upregulated in BC tissues compared to healthy controls, indicating its oncogenic role; moreover, its depletion by shRNA (small hairpin RNA) treatment in T24 and 5637 BC cell lines causes cell growth arrest and induction of apoptosis, suggesting that it is a possible BC therapeutic candidate [<xref ref-type="bibr" rid="B147-genes-08-00339">147</xref>].</p>
</sec>
<sec id="sec5dot18-genes-08-00339">
<title>5.18. PVT1</title>
<p>Plasmacytoma variant translocation (<italic>Pvt1</italic>) oncogene (<italic>PVT1</italic>) maps on chromosome 8q24.21, a locus that is frequently involved in t(2;8) translocations that are present in some human Burkitt lymphomas. PVT1 RNA and MYC protein expression correlate in several primary human tumors, and a direct relationship between copy number of PVT1 and MYC copy-increase has been found in more than 98% of human cancers. On the contrary, the PVT1 downregulation in the MYC-driven colon cancer cell line HCT116 reduced its tumorigenic potential, indicating a direct role of PVT1 in controlling MYC abundance. [<xref ref-type="bibr" rid="B148-genes-08-00339">148</xref>]; instead, the PVT1 overexpression is independent of MYC, at least in some cancers [<xref ref-type="bibr" rid="B149-genes-08-00339">149</xref>]. Similar studies were performed on BC samples as well, demonstrating that: (i) in BC, PVT1 is upregulated; indeed, in BC cells this lncRNA is highly correlated with histological grade and TNM stage. (ii) PVT1 silencing by shRNA inhibits the BC progression and promotes apoptosis [<xref ref-type="bibr" rid="B150-genes-08-00339">150</xref>]. Since MYC protein is refractory to small-molecule inhibition, the dependence of high MYC protein levels on PVT1 lncRNA suggests a promising way to therapeutically target this protein in MYC-positive cancers.</p>
</sec>
<sec id="sec5dot19-genes-08-00339">
<title>5.19. SChLAP1</title>
<p>The gene of the SWI/SNF complex antagonist associated with prostate cancer 1 (SChLAP1) maps on chromosome 2q31.3 and produces at least seven transcripts; however, more than 90% of these transcripts only belong to four splicing variants of 1.7, 1.4, 1.3 and 1.1 kb. It was originally isolated in aggressive prostate cancer, where its expression is in direct relationship with the metastasis formation [<xref ref-type="bibr" rid="B151-genes-08-00339">151</xref>]. In the same study, it was reported that the SChLAP1 knockdown in prostate cancer cell lines altered their gene expression profile in a way that was contrary to that of the SWI/SNF chromatin-modifying complex. The authors supported this finding by showing that this ncRNA coprecipitated with SMARCB1 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1), a subunit of the SWI/SNF complex and concluded that SChLAP1 antagonizes the SWI/SNF function by attenuating the binding to its genomic targets. Similar results were recently obtained in BC; however, the mechanisms of action of SChLAP1 still have to be elucidated [<xref ref-type="bibr" rid="B152-genes-08-00339">152</xref>].</p>
</sec>
<sec id="sec5dot20-genes-08-00339">
<title>5.20. SPRY4-IT1</title>
<p>SPRY4 intronic transcript 1 (SPRY4-IT1) is harbored inside the second intron of the <italic>SPRY4</italic> (sprouty RTK signaling antagonist 4) gene (an inhibitor of the MAPK kinase signaling pathway); this gene maps on chromosome 5q31.3. SPRY4-IT1, reportedly, is an unspliced, polyadenylated lncRNA with 708 nucleotides. It is not conserved among primates and, in normal human tissues, is most highly expressed in placenta, kidney, and lung [<xref ref-type="bibr" rid="B153-genes-08-00339">153</xref>]. In melanoma patient samples, its overexpression has been linked to cell proliferation, invasion and mobility; as expected, its knockdown causes opposite cellular effects, thus allowing classifying it as a potential oncogene [<xref ref-type="bibr" rid="B153-genes-08-00339">153</xref>]. Analogous results were obtained in other cellular systems, such as renal cancer, esophageal squamous cell carcinoma and trophoblast cells. Zhao et al. described a similar scenario in urothelial carcinoma of the bladder, where SPRY4-IT1 is overexpressed and significantly linked to histological grade, tumor stage, lymph node metastasis and reduced overall survival [<xref ref-type="bibr" rid="B154-genes-08-00339">154</xref>].</p>
</sec>
<sec id="sec5dot21-genes-08-00339">
<title>5.21. ZEB2-AS1</title>
<p>ZEB2 (zinc finger E-box binding homeobox 2, whose gene maps at position 2q22.3) is a transcriptional repressor of E-cadherin; it is upregulated after SNAI1-induced EMT. However, SNAI1 does not affect the synthesis of ZEB2 mRNA, but prevents the processing of a large intron located in its 5′-UTR region. ZEB2 Antisense RNA 1 (ZEB2-AS1, also named ZEB2 natural antisense transcript, ZEB2NAT) is the lncRNA contained inside the <italic>ZEB2</italic> locus and harbors an internal ribosome entry site necessary for the expression of Zeb2. The expression of this antisense transcript overlapping the 5′ splice site in the intron prevents the splicing of the ZEB2 5′-UTR and increases the quantity of the ZEB2 protein; this outcome downregulates E-cadherin both at the mRNA and protein levels [<xref ref-type="bibr" rid="B155-genes-08-00339">155</xref>]. In BC patient samples, the tumor invasiveness is driven by the TGFβ1 signaling pathway that promotes the EMT through cancer-associated fibroblasts (a major component of the cancer stroma); in this system, TGFβ1 is overexpressed in the presence of an upregulated ZEB2-AS1 (together with ZEB2) [<xref ref-type="bibr" rid="B156-genes-08-00339">156</xref>].</p>
</sec>
<sec id="sec5dot22-genes-08-00339">
<title>5.22. T-UCR 8+</title>
<p>Approximately 480 sequences in the human genome show a 100% identity with orthologous sequences in mice and rats, indicating that they went through a very strong negative selection for 300–400 million years; these regions are called ‘ultraconserved’ and some of them are transcribed as ncRNA [<xref ref-type="bibr" rid="B157-genes-08-00339">157</xref>]. In many cases, the function of these ncRNA is still to be explained; some are likely involved in splicing [<xref ref-type="bibr" rid="B158-genes-08-00339">158</xref>], others map next to transcriptional regulators or developmental genes, suggesting a related role for them [<xref ref-type="bibr" rid="B159-genes-08-00339">159</xref>], others are probably connected with cell proliferation, since they have copy number abnormalities in cancer tissues [<xref ref-type="bibr" rid="B160-genes-08-00339">160</xref>]. One of them has been linked to BC, i.e., ultraconserved RNA 8+ (uc.8+), located within the intron 1 of <italic>CASZ1</italic> (castor zinc finger 1, encoding a zinc-finger transcription factor), although it is expressed independently of <italic>CASZ1</italic> [<xref ref-type="bibr" rid="B56-genes-08-00339">56</xref>]. uc.8+ is the most upregulated T-UCR in BC tissues, but its expression is lower than in pericancerous bladder tissues. uc.8+ downregulation significantly reduces cancer cell invasion, migration and proliferation. Data available strongly suggest that uc.8+ is a natural trap for miR-596; as a result, the action of uc.8+ would be to deplete the intracellular availability of this miR and induce the upregulation of its targets, including MMP9 (matrix metalloprotease 9, involved in the degradation of extracellular matrix molecules), thus promoting cell proliferation and migration [<xref ref-type="bibr" rid="B56-genes-08-00339">56</xref>].</p>
</sec>
<sec id="sec5dot23-genes-08-00339">
<title>5.23. NEAT1</title>
<p>Nuclear enriched abundant transcript 1 (NEAT1) is a polyadenylated, unspliced ncRNA, which is abundantly transcribed in several cancers (bladder, lung, and breast) and promotes their development and progression; the same locus also encodes a short noncoding RNA, TncRNA (trophoblast-derived non-coding RNA), that originates from the 3’ end of NEAT1 and is exclusively expressed in trophoblasts [<xref ref-type="bibr" rid="B71-genes-08-00339">71</xref>]. <italic>NEAT1</italic> maps in the locus 11q13.1, less than 70 kb apart from <italic>MALAT1</italic>. Recently, Qian et al. demonstrated that its action in BC is performed through miR-101 tumor suppressor direct targeting that, successively, regulates EZH2 (enhancer of zeste homolog 2) function [<xref ref-type="bibr" rid="B161-genes-08-00339">161</xref>], while Ke et al. reported that NEAT1 is required for BC cell survival through FUS (fused in sarcoma) and miR-548 [<xref ref-type="bibr" rid="B162-genes-08-00339">162</xref>]. In an interesting recent article, it was described that: (i) NEAT1 is up-regulated in BC tissues and cell lines; and (ii) the knock-down of this lncRNA inhibits cell proliferation, suppresses cell migration and induces apoptosis in 5637, T24 and SW780 human BC cell lines [<xref ref-type="bibr" rid="B163-genes-08-00339">163</xref>].</p>
</sec>
<sec id="sec5dot24-genes-08-00339">
<title>5.24. Other lncRNA Deregulated in Bladder Cancer</title>
<p>For some BC-related lncRNA only preliminary evidence is available and/or data are clearly incomplete, especially as for mechanisms of action and target identification. In this section, we briefly mention cases that fall into this category.</p>
<p>Apoptosis-associated transcript in bladder cancer (AATBC, whose cytogenetic band is 21q22.3) is overexpressed in BC and positively correlates with tumor grade and pT stage; its inhibition causes cell proliferation arrest in G1 mediated by cyclin D1, CDK4, p18 and phosphorylated RB, as well as apoptosis induction through the intrinsic pathway [<xref ref-type="bibr" rid="B164-genes-08-00339">164</xref>].</p>
<p>Additionally, the search of new lncRNA is currently exploiting the ‘omics’ sciences, by analyzing the genome, the transcriptome, chromatin immunoprecipitation samples, etc. In this way, typically thousands of molecules are analyzed with a single experiment and bioinformatics analyses can be performed using the experimental output. Zhu et al. performed a microarray screening of lncRNAs in four pairs of human BC and matched normal tissues [<xref ref-type="bibr" rid="B118-genes-08-00339">118</xref>]. They could identify 110 lncRNA that are significantly (≥8 times) dysregulated in BC, and went on to validate by quantitative PCR (qPCR) four possible candidates (TNXA, CTA-134P22.2, CTC-276P9.1 and KRT19P3; <xref ref-type="table" rid="genes-08-00339-t002">Table 2</xref>), for which additional analyses are required to establish their role in this pathology. A similar approach has been used by Chen et al., who found out that lncRNA-n336928 is upregulated in BC, being positively correlated with BC grade and stage and negatively with patient survival [<xref ref-type="bibr" rid="B165-genes-08-00339">165</xref>]. Finally, Zhang et al. identified lncRNA-UNMIBC (long non-coding RNA-Up-regulated in non-muscle invasive bladder cancer) through a microarray analysis of lncRNA expression in BC samples. This molecule is upregulated in non-muscle invasive BC and the authors, through RNA and chromatin immunoprecipitation, showed that it is physically associated with EZH2 and SUZ12 (which are core components of PRC2), leading to an altered histone H3 lysine 27 methylation status of the target genes [<xref ref-type="bibr" rid="B166-genes-08-00339">166</xref>].</p>
<p>We conclude this paragraph by citing the articles of Peter et al. [<xref ref-type="bibr" rid="B167-genes-08-00339">167</xref>] and Wang et al. [<xref ref-type="bibr" rid="B168-genes-08-00339">168</xref>] as two examples of the growing complexity of the research in the field of lncRNA and BC. Both groups performed a genome-wide analysis of lncRNA differentially expressed in BC cells vs. normal urothelium. In the first article, the expression of 17,112 lncRNA was evaluated through microarray analysis; in this way, the authors identified 32 molecules potentially important in BC progression. They focused on AB074278, which was picked for the following features: “(i) associated with disease progression; (ii) upregulated in all urothelial cancer phenotypes […] (iii) had low predicted protein-coding scores (thus likely to be a ncRNA); (iv) worse outcomes with high expression (thus a potential oncogenic role); (v) also upregulated in urothelial cancer; and (vi) appeared of particular interest as it was intronic (sense direction) to a protein coding host gene (sense to TANC2; as were most validated ncRNAs in GENCODE) also upregulated in urothelial cancer (thus potentially regulated by the lncRNA […])” [<xref ref-type="bibr" rid="B167-genes-08-00339">167</xref>]. Notably, while AB074278 met these requirements, still there is no certainty in defining it as a ‘genuine’ upregulated lncRNA directly involved in the BC etiology and the identified interactions need further validation, exemplifying the difficulties of the scientists working in this field. As for the second paper [<xref ref-type="bibr" rid="B168-genes-08-00339">168</xref>], the authors examined the expression of 33,045 lncRNA through microarray analysis, revealing 3419 lncRNA differentially expressed in BC, with fold changes between 2 and 43 (1905 upregulated and 1514 downregulated). In addition, in this case, the identified lncRNA candidates need further, specific validation to understand their potential diagnostic and prognostic value in BC.</p>
</sec>
</sec>
<sec id="sec6-genes-08-00339">
<title>6. Small Non-Coding RNA</title>
<p>The definition of ‘small non-coding RNA’ includes many different, highly heterogeneous molecules (<xref ref-type="table" rid="genes-08-00339-t001">Table 1</xref>). Among them, a pivotal role in BC etiology is played by a specific class of RNAs, the microRNAs (also abbreviated in the literature as miRNA or miR). The study of miR is considered a great opportunity to better understand some pathological mechanisms, especially those linked to carcinogenesis. miR play important regulatory roles in animals and plants by targeting mRNAs for cleavage or translational repression [<xref ref-type="bibr" rid="B169-genes-08-00339">169</xref>]. Interestingly, these non-coding RNAs partly explain the (now obsolete) concept of ‘junk DNA’. After the completion of the human genome sequencing, it was evident that only 2% of the human DNA encodes functional proteins; 50% to 75% of the genome is transcribed, and 98% of the transcripts are not translated into proteins [<xref ref-type="bibr" rid="B170-genes-08-00339">170</xref>]. Non-coding RNAs are transcribed from approximately 70% of the genomic regions that used to be considered ‘junk DNA’ [<xref ref-type="bibr" rid="B171-genes-08-00339">171</xref>], i.e., meaningless DNA regions (from a genetic point of view). A significant number of miR are arranged in groups having an approximate length of 10 kb; this kind of organization is usually referred as ‘miR cluster’. The miR of a cluster are usually co-expressed, because they are under the control of a common promoter, and even share some target genes [<xref ref-type="bibr" rid="B172-genes-08-00339">172</xref>]. Moreover, miR also have some level of functional redundancy, as shown by sequence comparison, which likely is a useful backup system to protect normal cells from the malignant transformation [<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>].</p>
<p>As mentioned above, miR are usually ca. 22 nt long and their typical hairpin structure displays complementary pairing with their target mRNA [<xref ref-type="bibr" rid="B174-genes-08-00339">174</xref>]; therefore, it has been proven that a single sncRNA is able to target several mRNAs, usually by binding one of its ends or, in some cases, one of its internal sequences [<xref ref-type="bibr" rid="B175-genes-08-00339">175</xref>]. This field of molecular biology is extensively investigated because of its multiple implications for medicine (particularly medical oncology). In fact, the presence of miR not only in tissues but also in extracellular fluids (blood, urine and cerebrospinal fluid) suggests that these molecules can be used as informative biomarkers for the early diagnosis of diseases and as diagnostic tools in general [<xref ref-type="bibr" rid="B176-genes-08-00339">176</xref>]. miR can be roughly divided in two broad groups, according to the biological features and pathological mechanisms in which they are involved. miR which, upon upregulation, can be linked to a specific cancer are considered oncogenes; instead, miR whose downregulation takes part in carcinogenesis, are considered tumor suppressors. Indeed, miR activity in controlling gene expression, in cancer as well as in various other important diseases, makes them ideal candidates for therapeutic applications. Notably, miR selective modulation through antisense inhibition (for upregulated miR) or replacement (i.e., restoring a downregulated miR function by providing an external source of miR, through a vector overexpressing the targeted miR or transfecting a double-stranded miR) could significantly affect the prognosis of several diseases [<xref ref-type="bibr" rid="B177-genes-08-00339">177</xref>].</p>
<sec id="sec6dot1-genes-08-00339">
<title>6.1. Micro-RNA and Bladder Cancer</title>
<p>The involvement of different miR in the pathogenesis of BC is the subject of ongoing research. The goal is to clarify and exploit the use of miR as BC biomarkers, prognostic factors, and therapeutic targets [<xref ref-type="bibr" rid="B178-genes-08-00339">178</xref>], as well as in other pathological conditions linked to their altered expression. The list of miR that target genes involved in BC formation and development is already quite long. In 2011, Zhu et al. [<xref ref-type="bibr" rid="B179-genes-08-00339">179</xref>] reported the results of an NGS analysis that allowed identifying 226 differentially expressed miR in BC (182 upregulated and 44 downregulated); of these, 104 upregulated and 20 downregulated sequences were specific for BC, while the remaining were in common with other genitourinary malignancies (i.e., kidney and testicular cancer). In addition, Chen et al. [<xref ref-type="bibr" rid="B180-genes-08-00339">180</xref>] found tens of altered miR in BC—33 upregulated and 41 downregulated—when compared with normal bladder epithelium. Zobolotneva et al. described, through a systematic analysis of scientific reports, 95 differentially expressed miR, of which 48 were upregulated, 35 downregulated and 12 not clearly classifiable [<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]. In another study [<xref ref-type="bibr" rid="B182-genes-08-00339">182</xref>], the number of downregulated miR was 60, with 17 new potential miR identified. A recent meta-analysis on 473 papers published between 2009 and 2016 shows that at least 118 miR were identified multiple times in BC samples, or were detected in at least two out of three biological samples (tissue, blood, urine); of these, 111 miR were found in BC clinical specimens, with 57 downregulated or silenced, 51 overexpressed and the remaining cases contradictory [<xref ref-type="bibr" rid="B183-genes-08-00339">183</xref>]. Most likely these lists will become longer in the next few years, because of the great research effort that this field is producing. Indeed, through these investigations scientists hope to better understand the epigenetic mechanisms, which contribute to bladder carcinogenesis and to plan effective and targeted therapies. However, in most of these studies, only the deregulation of miR is considered, without any clue about the miR role in BC etiology. A recent meta-analysis performed by searching the PubMed and Google Scholar databases for publications ranging between 1990 and 2016 allowed identifying at least 35 miR specifically associated with different pathways of cellular dedifferentiation, proliferation, and progression of BC as well as of other cancers [<xref ref-type="bibr" rid="B184-genes-08-00339">184</xref>]. In this review, we have focused only on miR with an established role in urothelium neoplastic transformation by means of at least one identified target gene (<xref ref-type="table" rid="genes-08-00339-t003">Table 3</xref>) and have discussed only a few of them as prominent examples. However, since the choices made by different Authors to characterize miR target genes are based on very heterogeneous criteria, we have decided to collect all of them in this table as “proposed” targets. The role of these miR as oncogenes or tumor suppressor, according to their expression, is summarized in <xref ref-type="fig" rid="genes-08-00339-f001">Figure 1</xref>B.</p>
</sec>
<sec id="sec6dot2-genes-08-00339">
<title>6.2. The FGFR3 Pathway</title>
<p>Two main genetic pathways predispose to bladder carcinogenesis, for which the altered expression of miR is very important. Some miR, such as miR-99a, miR-100, miR-101, and miR-145, target the FGFR3 pathway, determining gain-of-function mutations, which are mostly detected in NMIBC; on the other hand, miR such as miR-21 and miR-373 cause loss-of-function mutations in the TP53 pathway, which are commonly found in MIBC [<xref ref-type="bibr" rid="B188-genes-08-00339">188</xref>].</p>
<p>The fibroblast growth factor (FGF) family of transmembrane tyrosine kinase receptors mediates proliferation in response to FGF stimulation and has been implicated in the pathogenesis of urothelial carcinoma: fibroblast growth factor receptor 3 (FGFR3) is frequently mutated or overexpressed in NMIBC [<xref ref-type="bibr" rid="B189-genes-08-00339">189</xref>]. For this reason, FGFR3 represents a useful BC biomarker with low malignant potential [<xref ref-type="bibr" rid="B190-genes-08-00339">190</xref>]. The evaluation of FGFR3 mutational status became relevant for human diseases when specific point mutations were discovered in various autosomal dominant human skeletal diseases, including achondroplasia, hypochondroplasia, thanatophoric dysplasia I and II, and severe achondroplasia with developmental delay and <italic>acanthosis nigrans</italic> (SADDAN) (reviewed in [<xref ref-type="bibr" rid="B191-genes-08-00339">191</xref>]). It was later shown that those mutations were also present in human bladder and cervix carcinomas [<xref ref-type="bibr" rid="B192-genes-08-00339">192</xref>]. Further investigations showed that <italic>FGFR3</italic> mutations occurred at a much higher rate in BC than in other tumor types (e.g., cervix, multiple myeloma, gastrointestinal tract, prostate) [<xref ref-type="bibr" rid="B193-genes-08-00339">193</xref>]. Several miR are involved in the FGFR3 pathway linked to BC formation and development (<xref ref-type="table" rid="genes-08-00339-t003">Table 3</xref>). For example, low levels of miR-100 were correlated with low-grade, non-invasive bladder urothelial cancer, due to the upregulation of FGFR3, meaning that, under physiological conditions, miR-100 acts as a tumor suppressor [<xref ref-type="bibr" rid="B194-genes-08-00339">194</xref>]. Similar activities are carried out also by miR-31, whose decreased expression has been described in the urothelial carcinoma of the bladder: miR-31 may contribute to the BC progression and is associated with unfavorable prognosis, overall and progression-free survival [<xref ref-type="bibr" rid="B195-genes-08-00339">195</xref>]. In addition, the downregulation of miR-99a leads to the upregulation of <italic>FGFR3</italic>, yet it is most commonly linked to low-grade tumors and better outcome [<xref ref-type="bibr" rid="B196-genes-08-00339">196</xref>]. miR-34a negatively regulates the cell cycle by reducing CCND1 (cyclin D1) and CDK4 (cyclin dependent kinase 4) levels; its downregulation promotes a more aggressive behavior of FGFR3 in urothelial carcinoma cases [<xref ref-type="bibr" rid="B197-genes-08-00339">197</xref>]. Other miR regulate this pathway, by acting either directly or indirectly on FGFR3 [<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>], as illustrated in <xref ref-type="table" rid="genes-08-00339-t003">Table 3</xref>; it is likely that the list of miR involved in the control of this gene will become longer in the future.</p>
</sec>
<sec id="sec6dot3-genes-08-00339">
<title>6.3. The TP53 Pathway</title>
<p>The other major genetic trigger, which can predispose to the formation and development of BC is represented by the loss of function of Tumor Protein p53 (TP53). TP53 is a transcription factor essential for the prevention of cancer formation in most human tissues. This gene encodes several protein isoforms, whose study has had a profound impact on our understanding of TP53 activity [<xref ref-type="bibr" rid="B198-genes-08-00339">198</xref>]. TP53 is one of the most important tumor suppressor genes: it provides essential functions in the cellular response to diverse stresses, safeguards the maintenance of genomic integrity and is a potent inducer of apoptosis and senescence when expressed in tumor cells [<xref ref-type="bibr" rid="B199-genes-08-00339">199</xref>]. TP53 can induce cell cycle arrest, DNA repair and, eventually, senescence and/or apoptosis; its mutations have been reported to occur in almost every type of cancer at rates varying between 10% (e.g., in hematopoietic malignancies) and almost 100% (e.g., in ovarian high-grade serous carcinoma) [<xref ref-type="bibr" rid="B200-genes-08-00339">200</xref>]. The frequency of molecular changes of this gene is substantially higher in MIBC (43.4%) than in NMIBC (8.2%), and a strong association exists between TP53 mutations and high tumor stage [<xref ref-type="bibr" rid="B201-genes-08-00339">201</xref>]. A computational analysis of the TP53 amino acid sequence has shown that this protein has remarkable similarities with prions [<xref ref-type="bibr" rid="B202-genes-08-00339">202</xref>] and experimental research has confirmed that amyloid formation can explain the negative dominance and loss of function of cancer-associated mutant TP53 [<xref ref-type="bibr" rid="B203-genes-08-00339">203</xref>,<xref ref-type="bibr" rid="B204-genes-08-00339">204</xref>]. Additionally, the TP53 pathway can be impaired by the action of several miR molecules, which may also induce loss-of-function (<xref ref-type="table" rid="genes-08-00339-t003">Table 3</xref>). For example, miR-205 has an ambivalent behavior as for the neoplastic transformation: indeed, it has many physiological and crucial roles, but its aberrant expression has been linked to the formation of many malignancies. miR-205 can act either as a tumor suppressive or an oncogenic miR, by regulating different cellular pathways such as those of cell survival, apoptosis, angiogenesis and metastasis, depending on its target genes [<xref ref-type="bibr" rid="B205-genes-08-00339">205</xref>]. Indeed, miR-205 is potentially able to target at the same time TP53, PTEN (Phosphatase and tensin homolog), c-erbB3 (a member of the epidermal growth factor receptor family of receptor tyrosine kinases), CDC42 (a protein involved in the cell cycle regulation), and YES (Yamaguchi sarcoma viral oncogene homolog) proto-oncogene 1 [<xref ref-type="bibr" rid="B206-genes-08-00339">206</xref>]. Therefore, miR-205 is possibly involved in many biochemical processes, including carcinogenesis. miR-205 may act as a diagnostic and prognostic BC marker, since it has been discovered that a mucosa with a normal appearance may have molecular changes (that precede phenotypic changes) in the form of varied expression of this molecule, besides other miR, such as miR-129 and miR-200a [<xref ref-type="bibr" rid="B184-genes-08-00339">184</xref>]. miR-21 targets many genes that can be involved in the formation and development of cancer, including TP53 [<xref ref-type="bibr" rid="B207-genes-08-00339">207</xref>], PTEN, TIMP3 (tissue inhibitor of metalloproteinase 3) (both inhibitors of the matrix metalloproteinases), BCL-2 (regulator of apoptosis) [<xref ref-type="bibr" rid="B208-genes-08-00339">208</xref>], and many others; its overexpression is linked to loss of function of TP53, which is most commonly observed in high-grade MIBC [<xref ref-type="bibr" rid="B209-genes-08-00339">209</xref>]. The overexpression of miR-373 is also found in BC, due to its many functions that promote carcinogenesis, cell invasion and metastasis [<xref ref-type="bibr" rid="B210-genes-08-00339">210</xref>]. Interestingly, miR-373 may act either as an oncogene or a tumor suppressor [<xref ref-type="bibr" rid="B210-genes-08-00339">210</xref>] and indirectly impairs TP53 function. Finally, some proteins regulated by miR, such as TP53 [<xref ref-type="bibr" rid="B211-genes-08-00339">211</xref>], the double-stranded RNA-specific endoribonuclease DROSHA and PTEN [<xref ref-type="bibr" rid="B212-genes-08-00339">212</xref>], are in turn able to regulate miR expression (<xref ref-type="table" rid="genes-08-00339-t003">Table 3</xref>); thus, some components of the miR maturation machinery are themselves under miR control in BC.</p>
</sec>
<sec id="sec6dot4-genes-08-00339">
<title>6.4. Other Molecular Pathways Causing miR-Mediated BC Formation</title>
<p>It is generally accepted that <italic>FGFR</italic>3 and <italic>TP</italic>53 alterations characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma and are hallmarks of specific BC types: <italic>FGFR3</italic> mutations are observed in 59% and <italic>TP53</italic> overexpression in 25% of primary BC. These alterations are almost mutually exclusive, since they overlap in only 5.7% of all tumors [<xref ref-type="bibr" rid="B213-genes-08-00339">213</xref>]; in addition, 15% of BC are normal with respect to both genes. However, it is well known that a single mutation is not sufficient to induce the neoplastic transformation, and that several tens of genes and different biochemical pathways are altered in BC samples at the same time, most of which have a direct role in cell cycle regulation, apoptosis, angiogenesis, cell–cell interaction, DNA repair, chromatin structure, gene expression, etc. [<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]. As shown in <xref ref-type="table" rid="genes-08-00339-t003">Table 3</xref>, there are several miR that do not target neither FGFR3 nor TP53, directly or indirectly [<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>], yet are deregulated in BC specimens; these data strongly suggest that the deregulation of several genes at the same time is required for the neoplastic transformation of the normal urothelium.</p>
</sec>
<sec id="sec6dot5-genes-08-00339">
<title>6.5. New Approaches for Assessing the miR-Mediated BC Formation</title>
<p>A peculiar point of view about the role played by miR in the formation and development of BC is that, in some cases, it is more informative to evaluate the ratio between two miR than to measure the total level of any single miR. For example, the miR-21:miR-205 expression ratio has the ability to distinguish between invasive and non-invasive bladder tumors with high sensitivity and specificity, and with the potential to identify superficial lesions that have a high risk of progression [<xref ref-type="bibr" rid="B206-genes-08-00339">206</xref>]. In another report, the ratio between miR-126 and miR-152 in the urine allowed the BC detection with a sensitivity of 72% and specificity of 82% [<xref ref-type="bibr" rid="B214-genes-08-00339">214</xref>]. Finally, a recent report shows that the miR-182:miR-100 ratio in BC specimens may fulfill several diagnostic requirements. In BC, miR-182 is usually upregulated, while miR-100 is downregulated. This ratio is associated with pT-stage, histological grade, BC recurrence and presence of carcinoma in situ; when this ratio is high, it is significantly correlated with shortened BC survival [<xref ref-type="bibr" rid="B215-genes-08-00339">215</xref>]. As a consequence, the miR-182:miR-100 ratio is a novel, non-invasive, promising biomarker for the diagnosis and survival assessments of BC patients.</p>
</sec>
</sec>
<sec id="sec7-genes-08-00339">
<title>7. Other ncRNA Involved in BC Etiology</title>
<p>As previously described, the epigenetic etiology of BC mostly involves two main categories of ncRNA, long ncRNA and miR. We conclude our review by mentioning a few other non-coding RNA molecules that have been linked to this pathology.</p>
<sec id="sec7dot1-genes-08-00339">
<title>7.1. Y RNA</title>
<p>Y RNA were originally identified as the RNA component of soluble ribonucleoproteins (RNPs) named Ro RNPs. Four human Y RNAs have been identified: Y1, Y3, Y4 and Y5 (Y2 is a truncated form of Y1). They have two recognized functions: repressors of Ro60 and other Ro proteins and initiation factors for the DNA replication [<xref ref-type="bibr" rid="B216-genes-08-00339">216</xref>]. In 2008 Christov et al. [<xref ref-type="bibr" rid="B217-genes-08-00339">217</xref>] found that two human Y RNA, namely hY1 and hY3, are significantly overexpressed in BC and several other tumors, and their RNA interference (RNAi)-mediated degradation results in a significant cytostatic (but not cytotoxic) effect in cell lines, probably by inducing a significant inhibition of chromosomal DNA replication in cultured human cells. These data, coupled with the fact that short fragments of Y RNAs have recently been identified as abundant components in the blood and tissues of humans and other mammals, make this class of ncRNA a valuable potential tool not only for diagnostic purposes, but also as a possible therapeutic target [<xref ref-type="bibr" rid="B218-genes-08-00339">218</xref>].</p>
</sec>
<sec id="sec7dot2-genes-08-00339">
<title>7.2. circRNA</title>
<p>Circular RNA (circRNA) are a class of RNA molecules that are covalently closed in a loop at the 3′ and 5′ ends. This peculiarity makes them more resistant than linear RNA to exonuclease-mediated degradation; indeed, their half-life is estimated to be approximately 48 h or more, while linear mRNA last on average 10 h [<xref ref-type="bibr" rid="B43-genes-08-00339">43</xref>]. circRNA can be generated via splicing from exons (exonic circRNA) or introns (intronic circRNA); these two classes, as well as a third class, i.e., retained-intron circular RNA, have distinct biogenesis patterns [<xref ref-type="bibr" rid="B219-genes-08-00339">219</xref>]. To date, their cellular role is still largely unknown. For some of them, it has been shown a role as miR sponges, i.e., they are able to bind miR without being degraded, thus preserving the mRNA target of the miR themselves [<xref ref-type="bibr" rid="B43-genes-08-00339">43</xref>]. In other cases, it has been proposed a role for circRNA, especially exonic ones, in the regulation of transcription or translation by direct targeting of the mRNA they come from, in such a way that their potential purposes are served through their mechanism of formation, rather than as final biological molecules [<xref ref-type="bibr" rid="B43-genes-08-00339">43</xref>]. In addition, their role as scaffold for the formation of RNA binding protein complexes cannot be ruled out [<xref ref-type="bibr" rid="B43-genes-08-00339">43</xref>]. Overall, circRNA have been described as potential decoys that interfere with the destination and function of their molecular counterparts and that have relevance in several cancer types [<xref ref-type="bibr" rid="B220-genes-08-00339">220</xref>]. Studies of circRNA in BC are still at the beginning, yet they are very promising. Zhong et al. demonstrated that at least six circRNA are highly expressed in human BC samples; in particular, circTCF25 can upregulate the levels of CDK6 by acting as a RNA sponge for miR-103a-3p and miR-107, thus promoting both cell proliferation and metastasis formation [<xref ref-type="bibr" rid="B221-genes-08-00339">221</xref>]. Similarly, circRNA-MYLK (encoded inside the myosin light chain kinase gene, MYLK) and circRNA-CTDP1 (mapping inside the gene encoding the subunit 1 of the phosphatase of the C-terminal domain of RNA polymerase II subunit A, CTDP1) can competitively bind miRNA-29a-3p and increase the expression of its target genes (DNMT3B, DNA methyltransferase 3 Beta; VEGFA, vascular endothelial growth factor A; HAS3, hyaluronan synthase 3; ITGB1, integrin subunit Beta 1), while circRNA-PC (inside the pyruvate carboxylase gene) is a competitor of miR-185-3p, a miR that targets ADD1 (adducin 1) and BAP1 (breast cancer 1 associated Protein 1) [<xref ref-type="bibr" rid="B83-genes-08-00339">83</xref>,<xref ref-type="bibr" rid="B222-genes-08-00339">222</xref>].</p>
</sec>
</sec>
<sec id="sec8-genes-08-00339">
<title>8. Conclusions</title>
<p>In the last years, significant steps have been taken towards the understanding of the role of epigenetics in human diseases in general, and cancer in particular. Far from being ‘junk DNA’, most of the human genome that does not code for proteins is important for cell homeostasis. Part of this genome is transcribed into RNA molecules of variable length, whose role in chromatin structure, gene expression, cell cycle control and (co-)regulation of many important biological pathways is currently investigated. RNA molecules with an altered expression in BC are many and, likely, their list will become larger in the future; indeed, important tools to identify and quantify these molecules are already available. We believe that the biggest challenges in this field will be precisely characterizing the functions of these RNAs inside the cells and taking advantage of this new knowledge to improve the health of BC patients.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>C.G., S.B., G.R., V.P., A.P. and R.P. collected data about lncRNA; C.G., S.B., F.S., M.G., V.B., A.P. and R.P. collected data about sncRNA; A.P. and R.P. coordinated the data collection; and A.P., R.P., C.G. and S.B. wrote the manuscript draft. All authors reviewed and approved the final version of the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-genes-08-00339">
<label>1.</label>
<element-citation publication-type="gov">
<article-title>US National Cancer Institute (NCI)</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.cancer.gov">http://www.cancer.gov</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2017-05-19">(accessed on 19 May 2017)</date-in-citation>
</element-citation>
</ref>
<ref id="B2-genes-08-00339">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erlich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zlotta</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Treatment of bladder cancer in the elderly</article-title>
<source/>Investig. Clin. Urol.
          <year>2016</year>
<volume>57</volume>
<fpage>S26</fpage>
<lpage>S35</lpage>
<pub-id pub-id-type="doi">10.4111/icu.2016.57.S1.S26</pub-id>
<pub-id pub-id-type="pmid">27326404</pub-id>
</element-citation>
</ref>
<ref id="B3-genes-08-00339">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Josephson</surname>
<given-names>D.Y.</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Cote</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Superficial bladder cancer: An update on etiology, molecular development, classification, and natural history</article-title>
<source/>Rev. Urol.
          <year>2008</year>
<volume>10</volume>
<fpage>31</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">18470273</pub-id>
</element-citation>
</ref>
<ref id="B4-genes-08-00339">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brooks</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>O’Donnell</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Treatment options in non-muscle-invasive bladder cancer after BCG failure</article-title>
<source/>Indian J. Urol.
          <year>2015</year>
<volume>31</volume>
<fpage>312</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.4103/0970-1591.166475</pub-id>
<pub-id pub-id-type="pmid">26604442</pub-id>
</element-citation>
</ref>
<ref id="B5-genes-08-00339">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scarpato</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Morgans</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Moses</surname>
<given-names>K.A.</given-names>
</name>
</person-group>
<article-title>Optimal management of muscle-invasive bladder cancer—A review</article-title>
<source/>Res. Rep. Urol.
          <year>2015</year>
<volume>7</volume>
<fpage>143</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="doi">10.2147/RRU.S73566</pub-id>
<pub-id pub-id-type="pmid">26380230</pub-id>
</element-citation>
</ref>
<ref id="B6-genes-08-00339">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.-T.</given-names>
</name>
<name>
<surname>Duymich</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Weisenberger</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Genetic and epigenetic alterations in bladder cancer</article-title>
<source/>Int. Neurourol. J.
          <year>2016</year>
<volume>20</volume>
<fpage>S84</fpage>
<lpage>S94</lpage>
<pub-id pub-id-type="doi">10.5213/inj.1632752.376</pub-id>
<pub-id pub-id-type="pmid">27915480</pub-id>
</element-citation>
</ref>
<ref id="B7-genes-08-00339">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernández</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>López-Knowles</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lloreta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kogevinas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jaramillo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Amorós</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tardón</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>García-Closas</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carrato</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>FGFR3</italic> and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis</article-title>
<source/>Clin. Cancer Res.
          <year>2005</year>
<volume>11</volume>
<fpage>5444</fpage>
<lpage>5450</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0122</pub-id>
<pub-id pub-id-type="pmid">16061860</pub-id>
</element-citation>
</ref>
<ref id="B8-genes-08-00339">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKnight</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>O’Kane</surname>
<given-names>H.F.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>K.E.</given-names>
</name>
</person-group>
<article-title>Apoptosis and chemotherapy for bladder cancer</article-title>
<source/>J. Urol.
          <year>2005</year>
<volume>173</volume>
<fpage>683</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.1097/01.ju.0000143194.79287.a9</pub-id>
<pub-id pub-id-type="pmid">15711244</pub-id>
</element-citation>
</ref>
<ref id="B9-genes-08-00339">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Margulis</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lotan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Montorsi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Shariat</surname>
<given-names>S.F.</given-names>
</name>
</person-group>
<article-title>Predicting survival after radical cystectomy for bladder cancer</article-title>
<source/>BJU Int.
          <year>2008</year>
<volume>102</volume>
<fpage>15</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.07594.x</pub-id>
<pub-id pub-id-type="pmid">18325050</pub-id>
</element-citation>
</ref>
<ref id="B10-genes-08-00339">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamana</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bilim</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kasahara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Itoi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tomita</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: Decreased expression of Fas is associated with disease progression</article-title>
<source/>Br. J. Cancer
          <year>2005</year>
<volume>93</volume>
<fpage>544</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6602732</pub-id>
<pub-id pub-id-type="pmid">16091761</pub-id>
</element-citation>
</ref>
<ref id="B11-genes-08-00339">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karam</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Lotan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Karakiewicz</surname>
<given-names>P.I.</given-names>
</name>
<name>
<surname>Ashfaq</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sagalowsky</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Roehrborn</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Shariat</surname>
<given-names>S.F.</given-names>
</name>
</person-group>
<article-title>Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy</article-title>
<source/>Lancet Oncol.
          <year>2007</year>
<volume>8</volume>
<fpage>128</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(07)70002-5</pub-id>
<pub-id pub-id-type="pmid">17267327</pub-id>
</element-citation>
</ref>
<ref id="B12-genes-08-00339">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shariat</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Ashfaq</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Karakiewicz</surname>
<given-names>P.I.</given-names>
</name>
<name>
<surname>Saeedi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Sagalowsky</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Lotan</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Survivin expression is associated with bladder cancer presence, stage, progression, and mortality</article-title>
<source/>Cancer
          <year>2007</year>
<volume>109</volume>
<fpage>1106</fpage>
<lpage>1113</lpage>
<pub-id pub-id-type="doi">10.1002/cncr.22521</pub-id>
<pub-id pub-id-type="pmid">17311310</pub-id>
</element-citation>
</ref>
<ref id="B13-genes-08-00339">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shariat</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Karam</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Lerner</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>Molecular markers in bladder cancer</article-title>
<source/>Curr. Opin. Urol.
          <year>2008</year>
<volume>18</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1097/MOU.0b013e3282f1c5c1</pub-id>
<pub-id pub-id-type="pmid">18090481</pub-id>
</element-citation>
</ref>
<ref id="B14-genes-08-00339">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shariat</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Youssef</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chade</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Karakiewicz</surname>
<given-names>P.I.</given-names>
</name>
<name>
<surname>Isbarn</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jeldres</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sagalowsky</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Ashfaq</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lotan</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers</article-title>
<source/>J. Urol.
          <year>2010</year>
<volume>183</volume>
<fpage>1744</fpage>
<lpage>1750</lpage>
<pub-id pub-id-type="doi">10.1016/j.juro.2010.01.018</pub-id>
<pub-id pub-id-type="pmid">20299037</pub-id>
</element-citation>
</ref>
<ref id="B15-genes-08-00339">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>H.-Y.</given-names>
</name>
<name>
<surname>Shariat</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T.-T.</given-names>
</name>
<name>
<surname>Lepor</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>J.-T.</given-names>
</name>
<name>
<surname>Ashfaq</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lotan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.-R.</given-names>
</name>
</person-group>
<article-title>Persistent uroplakin expression in advanced urothelial carcinomas: Implications in urothelial tumor progression and clinical outcome</article-title>
<source/>Hum. Pathol.
          <year>2007</year>
<volume>38</volume>
<fpage>1703</fpage>
<lpage>1713</lpage>
<pub-id pub-id-type="doi">10.1016/j.humpath.2007.04.003</pub-id>
<pub-id pub-id-type="pmid">17707461</pub-id>
</element-citation>
</ref>
<ref id="B16-genes-08-00339">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z.T.</given-names>
</name>
<name>
<surname>Pak</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Pellicer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.R.</given-names>
</name>
</person-group>
<article-title>Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation</article-title>
<source/>Oncogene
          <year>2001</year>
<volume>20</volume>
<fpage>1973</fpage>
<lpage>1980</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1204315</pub-id>
<pub-id pub-id-type="pmid">11360181</pub-id>
</element-citation>
</ref>
<ref id="B17-genes-08-00339">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Pierro</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>Gulia</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cristini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fraietta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Grande</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gentile</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Piergentili</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Bladder cancer: A simple model becomes complex</article-title>
<source/>Curr. Genom.
          <year>2012</year>
<volume>13</volume>
<fpage>395</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.2174/138920212801619232</pub-id>
<pub-id pub-id-type="pmid">23372425</pub-id>
</element-citation>
</ref>
<ref id="B18-genes-08-00339">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malats</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Real</surname>
<given-names>F.X.</given-names>
</name>
</person-group>
<article-title>Epidemiology of bladder cancer</article-title>
<source/>Hematol. Oncol. Clin. N. Am.
          <year>2015</year>
<volume>29</volume>
<fpage>177</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1016/j.hoc.2014.10.001</pub-id>
<pub-id pub-id-type="pmid">25836927</pub-id>
</element-citation>
</ref>
<ref id="B19-genes-08-00339">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeegers</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>F.E.</given-names>
</name>
<name>
<surname>Dorant</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>van den Brandt</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies</article-title>
<source/>Cancer
          <year>2000</year>
<volume>89</volume>
<fpage>630</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="doi">10.1002/1097-0142(20000801)89:3&lt;630::AID-CNCR19&gt;3.0.CO;2-Q</pub-id>
<pub-id pub-id-type="pmid">10931463</pub-id>
</element-citation>
</ref>
<ref id="B20-genes-08-00339">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cigarette smoke extract induces epithelial-mesenchymal transition of human bladder cancer T24 cells through activation of ERK1/2 pathway</article-title>
<source/>Biomed. Pharmacother.
          <year>2017</year>
<volume>86</volume>
<fpage>457</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2016.12.022</pub-id>
<pub-id pub-id-type="pmid">28012925</pub-id>
</element-citation>
</ref>
<ref id="B21-genes-08-00339">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaham</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Melzer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ribak</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Occupation and bladder cancer</article-title>
<source/>Harefuah
          <year>1996</year>
<volume>131</volume>
<fpage>382</fpage>
<lpage>386</lpage>
<pub-id pub-id-type="pmid">8981814</pub-id>
</element-citation>
</ref>
<ref id="B22-genes-08-00339">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marrett</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Hartge</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Meigs</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Bladder cancer and occupational exposure to leather</article-title>
<source/>Br. J. Ind. Med.
          <year>1986</year>
<volume>43</volume>
<fpage>96</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="doi">10.1136/oem.43.2.96</pub-id>
<pub-id pub-id-type="pmid">3947575</pub-id>
</element-citation>
</ref>
<ref id="B23-genes-08-00339">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverman</surname>
<given-names>D.T.</given-names>
</name>
<name>
<surname>Hartge</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Devesa</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>Epidemiology of bladder cancer</article-title>
<source/>Hematol. Oncol. Clin. N. Am.
          <year>1992</year>
<volume>6</volume>
<fpage>1</fpage>
<lpage>30</lpage>
</element-citation>
</ref>
<ref id="B24-genes-08-00339">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Hair dye use and risk of human cancer</article-title>
<source/>Front. Biosci. (Elite Ed)
          <year>2012</year>
<volume>4</volume>
<fpage>516</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="doi">10.2741/e397</pub-id>
<pub-id pub-id-type="pmid">22201892</pub-id>
</element-citation>
</ref>
<ref id="B25-genes-08-00339">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huncharek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kupelnick</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Personal use of hair dyes and the risk of bladder cancer: Results of a meta-analysis</article-title>
<source/>Public Health Rep.
          <year>2005</year>
<volume>120</volume>
<fpage>31</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1177/003335490512000107</pub-id>
<pub-id pub-id-type="pmid">15736329</pub-id>
</element-citation>
</ref>
<ref id="B26-genes-08-00339">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letašiová</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Medveďová</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Šovčíková</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dušinská</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Volkovová</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mosoiu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bartonová</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Bladder cancer, a review of the environmental risk factors</article-title>
<source/>Environ. Health
          <year>2012</year>
<volume>11</volume>
<fpage>S11</fpage>
<pub-id pub-id-type="doi">10.1186/1476-069X-11-S1-S11</pub-id>
<pub-id pub-id-type="pmid">22759493</pub-id>
</element-citation>
</ref>
<ref id="B27-genes-08-00339">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saint-Jacques</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dummer</surname>
<given-names>T.J.B.</given-names>
</name>
</person-group>
<article-title>Arsenic in drinking water and urinary tract cancers: A systematic review of 30 years of epidemiological evidence</article-title>
<source/>Environ. Health
          <year>2014</year>
<volume>13</volume>
<fpage>44</fpage>
<pub-id pub-id-type="doi">10.1186/1476-069X-13-44</pub-id>
<pub-id pub-id-type="pmid">24889821</pub-id>
</element-citation>
</ref>
<ref id="B28-genes-08-00339">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafa</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Sheweita</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Relationship between schistosomiasis and bladder cancer</article-title>
<source/>Clin. Microb. Rev.
          <year>1999</year>
<volume>12</volume>
<fpage>97</fpage>
<lpage>111</lpage>
</element-citation>
</ref>
<ref id="B29-genes-08-00339">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Handy</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Loscalzo</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Epigenetic modifications: Basic mechanisms and role in cardiovascular disease</article-title>
<source/>Circulation
          <year>2011</year>
<volume>123</volume>
<fpage>2145</fpage>
<lpage>2156</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.956839</pub-id>
<pub-id pub-id-type="pmid">21576679</pub-id>
</element-citation>
</ref>
<ref id="B30-genes-08-00339">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>S.C.P.</given-names>
</name>
</person-group>
<article-title>Epigenetics</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2013</year>
<volume>110</volume>
<fpage>3209</fpage>
<pub-id pub-id-type="doi">10.1073/pnas.1302488110</pub-id>
<pub-id pub-id-type="pmid">23417306</pub-id>
</element-citation>
</ref>
<ref id="B31-genes-08-00339">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaenisch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals</article-title>
<source/>Nat. Genet.
          <year>2003</year>
<volume>33</volume>
<fpage>245</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1038/ng1089</pub-id>
<pub-id pub-id-type="pmid">12610534</pub-id>
</element-citation>
</ref>
<ref id="B32-genes-08-00339">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murrell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hurd</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>I.C.</given-names>
</name>
</person-group>
<article-title>Epigenetic mechanisms in development and disease</article-title>
<source/>Biochem. Soc. Trans.
          <year>2013</year>
<volume>41</volume>
<fpage>697</fpage>
<lpage>699</lpage>
<pub-id pub-id-type="doi">10.1042/BST20130051</pub-id>
<pub-id pub-id-type="pmid">23697928</pub-id>
</element-citation>
</ref>
<ref id="B33-genes-08-00339">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bannister</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Kouzarides</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Regulation of chromatin by histone modifications</article-title>
<source/>Cell Res.
          <year>2011</year>
<volume>21</volume>
<fpage>381</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="doi">10.1038/cr.2011.22</pub-id>
<pub-id pub-id-type="pmid">21321607</pub-id>
</element-citation>
</ref>
<ref id="B34-genes-08-00339">
<label>34.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Collins</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Schönfeld</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>X.S.</given-names>
</name>
</person-group>
<article-title>The Epigenetics of Non-coding RNA</article-title>
<source/>Handbook of Epigenetics: The New Molecular and Medical Genetics
          <edition>1st ed.</edition>
<person-group person-group-type="editor">
<name>
<surname>Tollefsbol</surname>
<given-names>T.</given-names>
</name>
</person-group>
<publisher-name>Academic Press</publisher-name>
<publisher-loc>Cambridge, MA, USA</publisher-loc>
<year>2010</year>
<fpage>49</fpage>
<lpage>61</lpage>
</element-citation>
</ref>
<ref id="B35-genes-08-00339">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>C.Q.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.B.</given-names>
</name>
</person-group>
<article-title>Association between polymorphisms in microRNAs and risk of urological cancer: A meta-analysis based on 17,019 subjects</article-title>
<source/>Front. Physiol.
          <year>2017</year>
<volume>8</volume>
<fpage>325</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2017.00325</pub-id>
<pub-id pub-id-type="pmid">28579964</pub-id>
</element-citation>
</ref>
<ref id="B36-genes-08-00339">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arrigo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pulliero</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Effect of environmental chemical stress on nuclear noncoding RNA involved in epigenetic control</article-title>
<source/>Biomed. Res. Int.
          <year>2015</year>
<volume>2015</volume>
<fpage>761703</fpage>
<pub-id pub-id-type="doi">10.1155/2015/761703</pub-id>
<pub-id pub-id-type="pmid">26339639</pub-id>
</element-citation>
</ref>
<ref id="B37-genes-08-00339">
<label>37.</label>
<element-citation publication-type="book">
<article-title>IARC Monographs on the Evaluation of Carcinogenic Risks to Humans</article-title>
<publisher-name>International Agency for Research on Cancer</publisher-name>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://monographs.iarc.fr">https://monographs.iarc.fr</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2017-08-02">(accessed on 2 August 2017)</date-in-citation>
</element-citation>
</ref>
<ref id="B38-genes-08-00339">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ponting</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Hardison</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>What fraction of the human genome is functional?</article-title>
<source/>Genome Res.
          <year>2011</year>
<volume>21</volume>
<fpage>1769</fpage>
<lpage>1776</lpage>
<pub-id pub-id-type="doi">10.1101/gr.116814.110</pub-id>
<pub-id pub-id-type="pmid">21875934</pub-id>
</element-citation>
</ref>
<ref id="B39-genes-08-00339">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ling</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pichler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fodde</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Berindan-Neagoe</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Slack</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Calin</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Junk DNA and the long non-coding RNA twist in cancer genetics</article-title>
<source/>Oncogene
          <year>2015</year>
<volume>34</volume>
<fpage>5003</fpage>
<lpage>5011</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2014.456</pub-id>
<pub-id pub-id-type="pmid">25619839</pub-id>
</element-citation>
</ref>
<ref id="B40-genes-08-00339">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The functional role of long non-coding RNAs and epigenetics</article-title>
<source/>Biol. Proced. Online
          <year>2014</year>
<volume>16</volume>
<fpage>11</fpage>
<pub-id pub-id-type="doi">10.1186/1480-9222-16-11</pub-id>
<pub-id pub-id-type="pmid">25276098</pub-id>
</element-citation>
</ref>
<ref id="B41-genes-08-00339">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Soleimani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNA and cancer: A new paradigm</article-title>
<source/>Cancer Res.
          <year>2017</year>
<volume>77</volume>
<fpage>3965</fpage>
<lpage>3981</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2634</pub-id>
<pub-id pub-id-type="pmid">28701486</pub-id>
</element-citation>
</ref>
<ref id="B42-genes-08-00339">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>Z.H.</given-names>
</name>
</person-group>
<article-title>Transcribed ultraconserved region in human cancers</article-title>
<source/>RNA Biol.
          <year>2013</year>
<volume>10</volume>
<fpage>1771</fpage>
<lpage>1777</lpage>
<pub-id pub-id-type="doi">10.4161/rna.26995</pub-id>
<pub-id pub-id-type="pmid">24384562</pub-id>
</element-citation>
</ref>
<ref id="B43-genes-08-00339">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeck</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Sharpless</surname>
<given-names>N.E.</given-names>
</name>
</person-group>
<article-title>Detecting and characterizing circular RNAs</article-title>
<source/>Nat. Biotechnol.
          <year>2014</year>
<volume>32</volume>
<fpage>453</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2890</pub-id>
<pub-id pub-id-type="pmid">24811520</pub-id>
</element-citation>
</ref>
<ref id="B44-genes-08-00339">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carthew</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Sontheimer</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Origins and mechanisms of miRNAs and siRNAs</article-title>
<source/>Cell
          <year>2009</year>
<volume>136</volume>
<fpage>642</fpage>
<lpage>655</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.01.035</pub-id>
<pub-id pub-id-type="pmid">19239886</pub-id>
</element-citation>
</ref>
<ref id="B45-genes-08-00339">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Turnbull</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dalmay</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Y RNAs: Recent developments</article-title>
<source/>Biomol. Concepts
          <year>2013</year>
<volume>4</volume>
<fpage>103</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1515/bmc-2012-0050</pub-id>
<pub-id pub-id-type="pmid">25436569</pub-id>
</element-citation>
</ref>
<ref id="B46-genes-08-00339">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ha</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>V.N.</given-names>
</name>
</person-group>
<article-title>Regulation of microRNA biogenesis</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2014</year>
<volume>15</volume>
<fpage>509</fpage>
<lpage>524</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3838</pub-id>
<pub-id pub-id-type="pmid">25027649</pub-id>
</element-citation>
</ref>
<ref id="B47-genes-08-00339">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sohel</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Extracellular/circulating microRNAs: Release mechanisms, functions and challenges</article-title>
<source/>Achiev. Life Sci.
          <year>2016</year>
<volume>10</volume>
<fpage>175</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1016/j.als.2016.11.007</pub-id>
</element-citation>
</ref>
<ref id="B48-genes-08-00339">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siomi</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pezic</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Aravin</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>PIWI-interacting small RNAs: The vanguard of genome defence</article-title>
<source/>Nat. Rev. Mol. Cell. Biol.
          <year>2011</year>
<volume>12</volume>
<fpage>246</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3089</pub-id>
<pub-id pub-id-type="pmid">21427766</pub-id>
</element-citation>
</ref>
<ref id="B49-genes-08-00339">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bratkovič</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rogelj</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>The many faces of small nucleolar RNAs</article-title>
<source/>Biochim. Biophys. Acta
          <year>2014</year>
<volume>1839</volume>
<fpage>438</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.04.009</pub-id>
<pub-id pub-id-type="pmid">24735946</pub-id>
</element-citation>
</ref>
<ref id="B50-genes-08-00339">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matera</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Terns</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Terns</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Non-coding RNAs: Lessons from the small nuclear and small nucleolar RNAs</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2007</year>
<volume>8</volume>
<fpage>209</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1038/nrm2124</pub-id>
<pub-id pub-id-type="pmid">17318225</pub-id>
</element-citation>
</ref>
<ref id="B51-genes-08-00339">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Non-coding RNAs: An emerging player in DNA damage response</article-title>
<source/>Mutat. Res. Rev. Mutat. Res.
          <year>2015</year>
<volume>763</volume>
<fpage>202</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1016/j.mrrev.2014.11.003</pub-id>
<pub-id pub-id-type="pmid">25795121</pub-id>
</element-citation>
</ref>
<ref id="B52-genes-08-00339">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Adda di Fagagna</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>A direct role for small non-coding RNAs in DNA damage response</article-title>
<source/>Trends Cell Biol.
          <year>2014</year>
<volume>24</volume>
<fpage>171</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/j.tcb.2013.09.008</pub-id>
<pub-id pub-id-type="pmid">24156824</pub-id>
</element-citation>
</ref>
<ref id="B53-genes-08-00339">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hayashizaki</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>World of functional RNA</article-title>
<source/>Rinsho Shinkeigaku
          <year>2013</year>
<volume>53</volume>
<fpage>957</fpage>
<lpage>961</lpage>
<pub-id pub-id-type="doi">10.5692/clinicalneurol.53.957</pub-id>
<pub-id pub-id-type="pmid">24291846</pub-id>
</element-citation>
</ref>
<ref id="B54-genes-08-00339">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martens-Uzunova</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Böttcher</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Croce</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Jenster</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Visakorpi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Calin</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNA in prostate, bladder, and kidney cancer</article-title>
<source/>Eur. Urol.
          <year>2014</year>
<volume>65</volume>
<fpage>1140</fpage>
<lpage>1151</lpage>
<pub-id pub-id-type="doi">10.1016/j.eururo.2013.12.003</pub-id>
<pub-id pub-id-type="pmid">24373479</pub-id>
</element-citation>
</ref>
<ref id="B55-genes-08-00339">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sültmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Diederichs</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNA: “LNCs” to cancer</article-title>
<source/>Eur. Urol.
          <year>2014</year>
<volume>65</volume>
<fpage>1152</fpage>
<lpage>1153</lpage>
<pub-id pub-id-type="doi">10.1016/j.eururo.2014.01.032</pub-id>
<pub-id pub-id-type="pmid">24508069</pub-id>
</element-citation>
</ref>
<ref id="B56-genes-08-00339">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olivieri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ferro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Terreri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Durso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Romanelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Avitabile</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Cobelli</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Messere</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bruzzese</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vannini</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>20636</fpage>
<lpage>20654</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.7833</pub-id>
<pub-id pub-id-type="pmid">26943042</pub-id>
</element-citation>
</ref>
<ref id="B57-genes-08-00339">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ning</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lnc2Cancer: A manually curated database of experimentally supported lncRNAs associated with various human cancers</article-title>
<source/>Nucleic Acids Res.
          <year>2016</year>
<volume>44</volume>
<fpage>D980</fpage>
<lpage>D985</lpage>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.bio-bigdata.com/lnc2cancer/home.jsp">http://www.bio-bigdata.com/lnc2cancer/home.jsp</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2017-10-17">(accessed on 17 October 2017)</date-in-citation>
<pub-id pub-id-type="doi">10.1093/nar/gkv1094</pub-id>
<pub-id pub-id-type="pmid">26481356</pub-id>
</element-citation>
</ref>
<ref id="B58-genes-08-00339">
<label>58.</label>
<element-citation publication-type="web">
<article-title>GeneCards: The Human Gene Database</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.genecards.org">http://www.genecards.org</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2017-07-27">(accessed on 27 July 2017)</date-in-citation>
</element-citation>
</ref>
<ref id="B59-genes-08-00339">
<label>59.</label>
<element-citation publication-type="web">
<article-title>Online Mendelian Inheritance in Man (OMIM)</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.omim.org/">https://www.omim.org/</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2017-07-26">(accessed on 26 July 2017)</date-in-citation>
</element-citation>
</ref>
<ref id="B60-genes-08-00339">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells</article-title>
<source/>Gene
          <year>2012</year>
<volume>496</volume>
<fpage>8</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2012.01.012</pub-id>
<pub-id pub-id-type="pmid">22285928</pub-id>
</element-citation>
</ref>
<ref id="B61-genes-08-00339">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1α-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion</article-title>
<source/>Tumour Biol.
          <year>2014</year>
<volume>35</volume>
<fpage>6901</fpage>
<lpage>6912</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-014-1925-x</pub-id>
<pub-id pub-id-type="pmid">24737584</pub-id>
</element-citation>
</ref>
<ref id="B62-genes-08-00339">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis</article-title>
<source/>Tumour Biol.
          <year>2016</year>
<volume>37</volume>
<fpage>10633</fpage>
<lpage>10641</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-016-4917-1</pub-id>
<pub-id pub-id-type="pmid">26867765</pub-id>
</element-citation>
</ref>
<ref id="B63-genes-08-00339">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>miR-485-5p inhibits bladder cancer metastasis by targeting HMGA2</article-title>
<source/>Int. J. Mol. Med.
          <year>2015</year>
<volume>36</volume>
<fpage>1136</fpage>
<lpage>1142</lpage>
<pub-id pub-id-type="doi">10.3892/ijmm.2015.2302</pub-id>
<pub-id pub-id-type="pmid">26239806</pub-id>
</element-citation>
</ref>
<ref id="B64-genes-08-00339">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.-S.</given-names>
</name>
</person-group>
<article-title>Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma</article-title>
<source/>Clin. Cancer Res.
          <year>2006</year>
<volume>12</volume>
<fpage>4851</fpage>
<lpage>4858</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0134</pub-id>
<pub-id pub-id-type="pmid">16914571</pub-id>
</element-citation>
</ref>
<ref id="B65-genes-08-00339">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Accuracy of the urine UCA1 for diagnosis of bladder cancer: A meta-analysis</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>35222</fpage>
<lpage>35233</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.16473</pub-id>
<pub-id pub-id-type="pmid">28415640</pub-id>
</element-citation>
</ref>
<ref id="B66-genes-08-00339">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milowich</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Le Mercier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Neve</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sandras</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Roumeguere</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Decaestecker</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Salmon</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rorive</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Diagnostic value of the UCA1 test for bladder cancer detection: a clinical study</article-title>
<source/>SpringerPlus
          <year>2015</year>
<volume>4</volume>
<fpage>349</fpage>
<pub-id pub-id-type="doi">10.1186/s40064-015-1092-6</pub-id>
<pub-id pub-id-type="pmid">26191476</pub-id>
</element-citation>
</ref>
<ref id="B67-genes-08-00339">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Prognostic and clinicopathological role of long non-coding RNA UCA1 in various carcinomas</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>28373</fpage>
<lpage>28384</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.16059</pub-id>
<pub-id pub-id-type="pmid">28423704</pub-id>
</element-citation>
</ref>
<ref id="B68-genes-08-00339">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamouille</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Derynck</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of epithelial-mesenchymal transition</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2014</year>
<volume>15</volume>
<fpage>178</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3758</pub-id>
<pub-id pub-id-type="pmid">24556840</pub-id>
</element-citation>
</ref>
<ref id="B69-genes-08-00339">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiyomaru</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Enokida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tatarano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fujimura</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kikkawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Seki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer</article-title>
<source/>Br. J. Cancer
          <year>2010</year>
<volume>102</volume>
<fpage>883</fpage>
<lpage>891</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6605570</pub-id>
<pub-id pub-id-type="pmid">20160723</pub-id>
</element-citation>
</ref>
<ref id="B70-genes-08-00339">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway</article-title>
<source/>Cancer Sci.
          <year>2016</year>
<volume>107</volume>
<fpage>18</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1111/cas.12844</pub-id>
<pub-id pub-id-type="pmid">26544536</pub-id>
</element-citation>
</ref>
<ref id="B71-genes-08-00339">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hutchinson</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Ensminger</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Clemson</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Lawrence</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Chess</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains</article-title>
<source/>BMC Genomics
          <year>2007</year>
<volume>8</volume>
<elocation-id>39</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2164-8-39</pub-id>
<pub-id pub-id-type="pmid">17270048</pub-id>
</element-citation>
</ref>
<ref id="B72-genes-08-00339">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilusz</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Freier</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Spector</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>3’ End processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA</article-title>
<source/>Cell
          <year>2008</year>
<volume>135</volume>
<fpage>919</fpage>
<lpage>932</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.10.012</pub-id>
<pub-id pub-id-type="pmid">19041754</pub-id>
</element-citation>
</ref>
<ref id="B73-genes-08-00339">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNA MALAT1: Insights into its biogenesis and implications in human disease</article-title>
<source/>Curr. Pharm. Des.
          <year>2015</year>
<volume>21</volume>
<fpage>5017</fpage>
<lpage>5028</lpage>
<pub-id pub-id-type="doi">10.2174/1381612821666150724115625</pub-id>
<pub-id pub-id-type="pmid">26205289</pub-id>
</element-citation>
</ref>
<ref id="B74-genes-08-00339">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: Systematic review and meta-analysis</article-title>
<source/>BMJ Open
          <year>2015</year>
<volume>5</volume>
<fpage>e008653</fpage>
<pub-id pub-id-type="doi">10.1136/bmjopen-2015-008653</pub-id>
<pub-id pub-id-type="pmid">26423854</pub-id>
</element-citation>
</ref>
<ref id="B75-genes-08-00339">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Role of MALAT1 as a prognostic factor for survival in various cancers: A systematic review of the literature with meta-analysis</article-title>
<source/>Dis. Markers
          <year>2015</year>
<volume>2015</volume>
<fpage>164635</fpage>
<pub-id pub-id-type="doi">10.1155/2015/164635</pub-id>
<pub-id pub-id-type="pmid">26420912</pub-id>
</element-citation>
</ref>
<ref id="B76-genes-08-00339">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition</article-title>
<source/>Mol. Biosyst.
          <year>2012</year>
<volume>8</volume>
<fpage>2289</fpage>
<lpage>2294</lpage>
<pub-id pub-id-type="doi">10.1039/c2mb25070e</pub-id>
<pub-id pub-id-type="pmid">22722759</pub-id>
</element-citation>
</ref>
<ref id="B77-genes-08-00339">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Prognostic value of long non-coding RNA MALAT1 in cancer patients</article-title>
<source/>Tumour Biol.
          <year>2016</year>
<volume>37</volume>
<fpage>897</fpage>
<lpage>903</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-015-3870-8</pub-id>
<pub-id pub-id-type="pmid">26254614</pub-id>
</element-citation>
</ref>
<ref id="B78-genes-08-00339">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smits</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mungall</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Griffiths-Jones</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Beury</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pask</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>VandeBerg</surname>
<given-names>J.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Conservation of the H19 noncoding RNA and H19-IGF2 imprinting mechanism in therians</article-title>
<source/>Nat. Genet.
          <year>2008</year>
<volume>40</volume>
<fpage>971</fpage>
<lpage>976</lpage>
<pub-id pub-id-type="doi">10.1038/ng.168</pub-id>
<pub-id pub-id-type="pmid">18587395</pub-id>
</element-citation>
</ref>
<ref id="B79-genes-08-00339">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabory</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jammes</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dandolo</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The <italic>H19</italic> locus: Role of an imprinted non-coding RNA in growth and development</article-title>
<source/>Bioessays
          <year>2010</year>
<volume>32</volume>
<fpage>473</fpage>
<lpage>480</lpage>
<pub-id pub-id-type="doi">10.1002/bies.200900170</pub-id>
<pub-id pub-id-type="pmid">20486133</pub-id>
</element-citation>
</ref>
<ref id="B80-genes-08-00339">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariel</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sughayer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fellig</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pizov</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ayesh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Podeh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Libdeh</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Birman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tykocinski</surname>
<given-names>M.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The imprinted <italic>H19</italic> gene is a marker of early recurrence in human bladder carcinoma</article-title>
<source/>Mol. Pathol.
          <year>2000</year>
<volume>53</volume>
<fpage>320</fpage>
<lpage>323</lpage>
<pub-id pub-id-type="doi">10.1136/mp.53.6.320</pub-id>
<pub-id pub-id-type="pmid">11193051</pub-id>
</element-citation>
</ref>
<ref id="B81-genes-08-00339">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byun</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>H.-L.</given-names>
</name>
<name>
<surname>Aaron</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>A.S.</given-names>
</name>
</person-group>
<article-title>Examination of IGF2 and H19 loss of imprinting in bladder cancer</article-title>
<source/>Cancer Res
          <year>2007</year>
<volume>67</volume>
<fpage>10753</fpage>
<lpage>10758</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0329</pub-id>
<pub-id pub-id-type="pmid">18006818</pub-id>
</element-citation>
</ref>
<ref id="B82-genes-08-00339">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariel</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hochberg</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Imprinted <italic>H19</italic> gene expression in embryogenesis and human cancer: The oncofetal connection</article-title>
<source/>Am. J. Med. Genet.
          <year>2000</year>
<volume>91</volume>
<fpage>46</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(20000306)91:1&lt;46::AID-AJMG8&gt;3.0.CO;2-I</pub-id>
<pub-id pub-id-type="pmid">10751088</pub-id>
</element-citation>
</ref>
<ref id="B83-genes-08-00339">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Comprehensive analysis of differentially expressed profiles of lncRNAs and circRNAs with associated co-expression and ceRNA networks in bladder carcinoma</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>47186</fpage>
<lpage>47200</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.9706</pub-id>
<pub-id pub-id-type="pmid">27363013</pub-id>
</element-citation>
</ref>
<ref id="B84-genes-08-00339">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gielchinsky</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gilon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abu-Lail</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Matouk</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hochberg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gofrit</surname>
<given-names>O.N.</given-names>
</name>
<name>
<surname>Ben-Dov</surname>
<given-names>I.Z.</given-names>
</name>
</person-group>
<article-title>H19 non-coding RNA in urine cells detects urothelial carcinoma: A pilot study</article-title>
<source/>Biomarkers
          <year>2017</year>
<volume>22</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1080/1354750X.2016.1276625</pub-id>
<pub-id pub-id-type="pmid">27319431</pub-id>
</element-citation>
</ref>
<ref id="B85-genes-08-00339">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>B.R.</given-names>
</name>
</person-group>
<article-title>The imprinted H19 noncoding RNA is a primary microRNA precursor</article-title>
<source/>RNA
          <year>2007</year>
<volume>13</volume>
<fpage>313</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1261/rna.351707</pub-id>
<pub-id pub-id-type="pmid">17237358</pub-id>
</element-citation>
</ref>
<ref id="B86-genes-08-00339">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartholdi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Krajewska-Walasek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ounap</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chrzanowska</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Ilyana</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kayserili</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lurie</surname>
<given-names>I.W.</given-names>
</name>
<name>
<surname>Schinzel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Baumer</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome (SRS): Results from a large cohort of patients with SRS and SRS-like phenotypes</article-title>
<source/>J. Med. Genet.
          <year>2009</year>
<volume>46</volume>
<fpage>192</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2008.061820</pub-id>
<pub-id pub-id-type="pmid">19066168</pub-id>
</element-citation>
</ref>
<ref id="B87-genes-08-00339">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forné</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Oswald</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Saam</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Bailleul</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dandolo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tilghman</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reik</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Loss of the maternal <italic>H19</italic> gene induces changes in Igf2 methylation in both cis and trans</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1997</year>
<volume>94</volume>
<fpage>10243</fpage>
<lpage>10248</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.94.19.10243</pub-id>
<pub-id pub-id-type="pmid">9294195</pub-id>
</element-citation>
</ref>
<ref id="B88-genes-08-00339">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ripoche</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Kress</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Poirier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dandolo</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element</article-title>
<source/>Genes Dev.
          <year>1997</year>
<volume>11</volume>
<fpage>1596</fpage>
<lpage>1604</lpage>
<pub-id pub-id-type="doi">10.1101/gad.11.12.1596</pub-id>
<pub-id pub-id-type="pmid">9203585</pub-id>
</element-citation>
</ref>
<ref id="B89-genes-08-00339">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ohsumi</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Kung</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Grau</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Sarma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Kingston</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Borowsky</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.T.</given-names>
</name>
</person-group>
<article-title>Genome-wide identification of polycomb-associated RNAs by RIP-seq</article-title>
<source/>Mol. Cell
          <year>2010</year>
<volume>40</volume>
<fpage>939</fpage>
<lpage>953</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2010.12.011</pub-id>
<pub-id pub-id-type="pmid">21172659</pub-id>
</element-citation>
</ref>
<ref id="B90-genes-08-00339">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Herrick</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Brewer</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells</article-title>
<source/>J. Biol. Chem.
          <year>2005</year>
<volume>280</volume>
<fpage>18517</fpage>
<lpage>18524</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M500270200</pub-id>
<pub-id pub-id-type="pmid">15753088</pub-id>
</element-citation>
</ref>
<ref id="B91-genes-08-00339">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation</article-title>
<source/>Tumour Biol.
          <year>2016</year>
<volume>37</volume>
<fpage>263</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-015-3779-2</pub-id>
<pub-id pub-id-type="pmid">26198047</pub-id>
</element-citation>
</ref>
<ref id="B92-genes-08-00339">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsang</surname>
<given-names>W.P.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>E.K.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>T.T.</given-names>
</name>
</person-group>
<article-title>Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer</article-title>
<source/>Carcinogenesis
          <year>2010</year>
<volume>31</volume>
<fpage>350</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgp181</pub-id>
<pub-id pub-id-type="pmid">19926638</pub-id>
</element-citation>
</ref>
<ref id="B93-genes-08-00339">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devor</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>De Mik</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Schickling</surname>
<given-names>B.M.</given-names>
</name>
</person-group>
<article-title>Conserved sequences and secondary RNA structures confirm that H19 functions as a pri-miRNA and as an RNA-binding protein platform</article-title>
<source/>Open Genom. J.
          <year>2013</year>
<volume>6</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.2174/1875693X20130703001</pub-id>
</element-citation>
</ref>
<ref id="B94-genes-08-00339">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cepko</surname>
<given-names>C.L.</given-names>
</name>
</person-group>
<article-title>The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina</article-title>
<source/>Curr. Biol.
          <year>2005</year>
<volume>15</volume>
<fpage>501</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1016/j.cub.2005.02.027</pub-id>
<pub-id pub-id-type="pmid">15797018</pub-id>
</element-citation>
</ref>
<ref id="B95-genes-08-00339">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khalil</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Guttman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huarte</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garber</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Raj</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Presser</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>van Oudenaarden</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression</article-title>
<source/>Proc. Nat. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>11667</fpage>
<lpage>11672</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0904715106</pub-id>
<pub-id pub-id-type="pmid">19571010</pub-id>
</element-citation>
</ref>
<ref id="B96-genes-08-00339">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>M.T.V.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.K.K.</given-names>
</name>
</person-group>
<article-title>TUG1: A pivotal oncogenic long non-coding RNA of human cancers</article-title>
<source/>Cell Prolif.
          <year>2016</year>
<volume>49</volume>
<fpage>471</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.1111/cpr.12269</pub-id>
<pub-id pub-id-type="pmid">27339553</pub-id>
</element-citation>
</ref>
<ref id="B97-genes-08-00339">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Downregulation of long noncoding RNA TUG1 inhibits proliferation and induces apoptosis through the TUG1/miR-142/ZEB2 axis in bladder cancer cells</article-title>
<source/>Onco. Targets Ther.
          <year>2017</year>
<volume>10</volume>
<fpage>2461</fpage>
<lpage>2471</lpage>
<pub-id pub-id-type="doi">10.2147/OTT.S124595</pub-id>
<pub-id pub-id-type="pmid">28503069</pub-id>
</element-citation>
</ref>
<ref id="B98-genes-08-00339">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iliev</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kleinova</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Juracek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dolezel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ozanova</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fedorko</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pacik</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Svoboda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stanik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Slaby</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer</article-title>
<source/>Tumor Biol.
          <year>2016</year>
<volume>37</volume>
<fpage>13385</fpage>
<lpage>13390</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-016-5177-9</pub-id>
<pub-id pub-id-type="pmid">27460088</pub-id>
</element-citation>
</ref>
<ref id="B99-genes-08-00339">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guttman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Amit</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Garber</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Feldser</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huarte</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zuk</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Cassady</surname>
<given-names>J.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals</article-title>
<source/>Nature
          <year>2009</year>
<volume>458</volume>
<fpage>223</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1038/nature07672</pub-id>
<pub-id pub-id-type="pmid">19182780</pub-id>
</element-citation>
</ref>
<ref id="B100-genes-08-00339">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Klibanski</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Maternally expressed gene 3 (<italic>MEG3</italic>) noncoding ribonucleic acid: Isoform structure, expression, and functions</article-title>
<source/>Endocrinology
          <year>2010</year>
<volume>151</volume>
<fpage>939</fpage>
<lpage>947</lpage>
<pub-id pub-id-type="doi">10.1210/en.2009-0657</pub-id>
<pub-id pub-id-type="pmid">20032057</pub-id>
</element-citation>
</ref>
<ref id="B101-genes-08-00339">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyoshi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wagatsuma</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wakana</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shiroishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aisaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kohda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Surani</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Kaneko-Ishino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ishino</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Identification of an imprinted gene, <italic>MEG3/GTL2</italic> and its human homologue <italic>MEG3</italic>, first mapped on mouse distal chromosome 12 and human chromosome 14q</article-title>
<source/>Genes Cells
          <year>2000</year>
<volume>5</volume>
<fpage>211</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2443.2000.00320.x</pub-id>
<pub-id pub-id-type="pmid">10759892</pub-id>
</element-citation>
</ref>
<ref id="B102-genes-08-00339">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Paulsen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tevendale</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C.-E.</given-names>
</name>
<name>
<surname>Kelsey</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cattanach</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Ferguson-Smith</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>Epigenetic analysis of the DLK1-GTL2 imprinted domain on mouse chromosome 12: Implications for imprinting control from comparison with IGF2-H19</article-title>
<source/>Hum. Mol. Genet.
          <year>2002</year>
<volume>11</volume>
<fpage>77</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/11.1.77</pub-id>
<pub-id pub-id-type="pmid">11773001</pub-id>
</element-citation>
</ref>
<ref id="B103-genes-08-00339">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLaughlin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vidaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Renieri</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Karagogeos</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Expression pattern of the maternally imprinted gene GTL2 in the forebrain during embryonic development and adulthood</article-title>
<source/>Gene Expr. Patterns
          <year>2006</year>
<volume>6</volume>
<fpage>394</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1016/j.modgep.2005.09.007</pub-id>
<pub-id pub-id-type="pmid">16356785</pub-id>
</element-citation>
</ref>
<ref id="B104-genes-08-00339">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Danila</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Scolavino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Klibanski</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2003</year>
<volume>88</volume>
<fpage>5119</fpage>
<lpage>5126</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2003-030222</pub-id>
<pub-id pub-id-type="pmid">14602737</pub-id>
</element-citation>
</ref>
<ref id="B105-genes-08-00339">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michelhaugh</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Lipovich</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Blythe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kapatos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bannon</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Mining Affymetrix microarray data for long non-coding RNAs: Altered expression in the nucleus accumbens of heroin abusers</article-title>
<source/>J. Neurochem.
          <year>2011</year>
<volume>116</volume>
<fpage>459</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.07126.x</pub-id>
<pub-id pub-id-type="pmid">21128942</pub-id>
</element-citation>
</ref>
<ref id="B106-genes-08-00339">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNAs in Huntington’s disease neurodegeneration</article-title>
<source/>Neurobiol. Dis.
          <year>2012</year>
<volume>46</volume>
<fpage>245</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2011.12.006</pub-id>
<pub-id pub-id-type="pmid">22202438</pub-id>
</element-citation>
</ref>
<ref id="B107-genes-08-00339">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mondal</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Isaksson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kanduri</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Characterization of the RNA content of chromatin</article-title>
<source/>Genome Res.
          <year>2010</year>
<volume>20</volume>
<fpage>899</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="doi">10.1101/gr.103473.109</pub-id>
<pub-id pub-id-type="pmid">20404130</pub-id>
</element-citation>
</ref>
<ref id="B108-genes-08-00339">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gejman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mahta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheunsuchon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Klibanski</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression</article-title>
<source/>Cancer Res.
          <year>2010</year>
<volume>70</volume>
<fpage>2350</fpage>
<lpage>2358</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3885</pub-id>
<pub-id pub-id-type="pmid">20179190</pub-id>
</element-citation>
</ref>
<ref id="B109-genes-08-00339">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Batista</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Gejman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ansell</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Klibanski</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Activation of p53 by MEG3 non-coding RNA</article-title>
<source/>J. Biol. Chem.
          <year>2007</year>
<volume>282</volume>
<fpage>24731</fpage>
<lpage>24742</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M702029200</pub-id>
<pub-id pub-id-type="pmid">17569660</pub-id>
</element-citation>
</ref>
<ref id="B110-genes-08-00339">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>F.E.</given-names>
</name>
<name>
<surname>Nutt</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Cheunsuchon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Provencher</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Klibanski</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Increased expression of angiogenic genes in the brains of mouse <italic>MEG3</italic>-null embryos</article-title>
<source/>Endocrinology
          <year>2010</year>
<volume>151</volume>
<fpage>2443</fpage>
<lpage>2452</lpage>
<pub-id pub-id-type="doi">10.1210/en.2009-1151</pub-id>
<pub-id pub-id-type="pmid">20392836</pub-id>
</element-citation>
</ref>
<ref id="B111-genes-08-00339">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Downregulated <italic>MEG3</italic> activates autophagy and increases cell proliferation in bladder cancer</article-title>
<source/>Mol. Biosyst.
          <year>2013</year>
<volume>9</volume>
<fpage>407</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="doi">10.1039/c2mb25386k</pub-id>
<pub-id pub-id-type="pmid">23295831</pub-id>
</element-citation>
</ref>
<ref id="B112-genes-08-00339">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greife</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Knievel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ribarska</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Niegisch</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>W.A.</given-names>
</name>
</person-group>
<article-title>Concomitant downregulation of the imprinted genes DLK1 and <italic>MEG3</italic> at 14q32.2 by epigenetic mechanisms in urothelial carcinoma</article-title>
<source/>Clin. Epigenetics
          <year>2014</year>
<volume>6</volume>
<fpage>29</fpage>
<pub-id pub-id-type="doi">10.1186/1868-7083-6-29</pub-id>
<pub-id pub-id-type="pmid">25741387</pub-id>
</element-citation>
</ref>
<ref id="B113-genes-08-00339">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>78850</fpage>
<lpage>78858</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.12880</pub-id>
<pub-id pub-id-type="pmid">27793008</pub-id>
</element-citation>
</ref>
<ref id="B114-genes-08-00339">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2014</year>
<volume>446</volume>
<fpage>448</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2014.02.144</pub-id>
<pub-id pub-id-type="pmid">24631686</pub-id>
</element-citation>
</ref>
<ref id="B115-genes-08-00339">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Augoff</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McCue</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Plow</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Sossey-Alaoui</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer</article-title>
<source/>Mol. Cancer
          <year>2012</year>
<volume>11</volume>
<fpage>5</fpage>
<pub-id pub-id-type="doi">10.1186/1476-4598-11-5</pub-id>
<pub-id pub-id-type="pmid">22289355</pub-id>
</element-citation>
</ref>
<ref id="B116-genes-08-00339">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Decreased expression of LncRNA MIR31HG in human bladder cancer</article-title>
<source/>Cancer Biomark.
          <year>2016</year>
<volume>17</volume>
<fpage>231</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.3233/CBM-160635</pub-id>
<pub-id pub-id-type="pmid">27434291</pub-id>
</element-citation>
</ref>
<ref id="B117-genes-08-00339">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer</article-title>
<source/>Biochim. Biophys. Acta
          <year>2013</year>
<volume>1832</volume>
<fpage>1528</fpage>
<lpage>1537</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2013.05.010</pub-id>
<pub-id pub-id-type="pmid">23688781</pub-id>
</element-citation>
</ref>
<ref id="B118-genes-08-00339">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.P.</given-names>
</name>
<name>
<surname>Bian</surname>
<given-names>X.J.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X.D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.J.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNA expression signatures of bladder cancer revealed by microarray</article-title>
<source/>Oncol. Lett.
          <year>2014</year>
<volume>7</volume>
<fpage>1197</fpage>
<lpage>1202</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2014.1843</pub-id>
<pub-id pub-id-type="pmid">24944692</pub-id>
</element-citation>
</ref>
<ref id="B119-genes-08-00339">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA LOC572558 inhibits bladder cancer cell proliferation and tumor growth by regulating the AKT-MDM2-p53 signaling axis</article-title>
<source/>Cancer Lett.
          <year>2016</year>
<volume>380</volume>
<fpage>369</fpage>
<lpage>374</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2016.04.030</pub-id>
<pub-id pub-id-type="pmid">27130667</pub-id>
</element-citation>
</ref>
<ref id="B120-genes-08-00339">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Koegel</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Kotake</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Horlings</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Umbricht</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters</article-title>
<source/>Nature Genet.
          <year>2011</year>
<volume>43</volume>
<fpage>621</fpage>
<lpage>629</lpage>
<pub-id pub-id-type="doi">10.1038/ng.848</pub-id>
<pub-id pub-id-type="pmid">21642992</pub-id>
</element-citation>
</ref>
<ref id="B121-genes-08-00339">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer</article-title>
<source/>J. Exp. Clin. Cancer Res.
          <year>2016</year>
<volume>35</volume>
<fpage>83</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-016-0354-7</pub-id>
<pub-id pub-id-type="pmid">27206339</pub-id>
</element-citation>
</ref>
<ref id="B122-genes-08-00339">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotake</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kitagawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ohhata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Niida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Naemura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kitagawa</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA, PANDA, contributes to the stabilization of p53 tumor suppressor protein</article-title>
<source/>Anticancer Res.
          <year>2016</year>
<volume>36</volume>
<fpage>1605</fpage>
<lpage>1612</lpage>
<pub-id pub-id-type="pmid">27069137</pub-id>
</element-citation>
</ref>
<ref id="B123-genes-08-00339">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability</article-title>
<source/>FEBS J.
          <year>2014</year>
<volume>281</volume>
<fpage>802</fpage>
<lpage>813</lpage>
<pub-id pub-id-type="doi">10.1111/febs.12625</pub-id>
<pub-id pub-id-type="pmid">24397586</pub-id>
</element-citation>
</ref>
<ref id="B124-genes-08-00339">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>Z.L.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNA GHET1 promotes the development of bladder cancer</article-title>
<source/>Int. J. Clin. Exp. Pathol.
          <year>2014</year>
<volume>7</volume>
<fpage>7196</fpage>
<lpage>7205</lpage>
<pub-id pub-id-type="pmid">25400817</pub-id>
</element-citation>
</ref>
<ref id="B125-genes-08-00339">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and survival</article-title>
<source/>Urology
          <year>2011</year>
<volume>77</volume>
<fpage>510.e1</fpage>
<lpage>510.e5</lpage>
<pub-id pub-id-type="doi">10.1016/j.urology.2010.09.022</pub-id>
<pub-id pub-id-type="pmid">21147498</pub-id>
</element-citation>
</ref>
<ref id="B126-genes-08-00339">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Niizuma</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Oo</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Isogai</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Koda</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A high expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma</article-title>
<source/>Int. J. Oncol.
          <year>2009</year>
<volume>34</volume>
<fpage>931</fpage>
<lpage>938</lpage>
<pub-id pub-id-type="pmid">19287950</pub-id>
</element-citation>
</ref>
<ref id="B127-genes-08-00339">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Steitz</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host gene and a member of the 5-prime terminal oligopyrimidine gene family reveals common features of snoRNA host genes</article-title>
<source/>Mol. Cell. Biol.
          <year>1998</year>
<volume>18</volume>
<fpage>6897</fpage>
<lpage>6909</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.18.12.6897</pub-id>
<pub-id pub-id-type="pmid">9819378</pub-id>
</element-citation>
</ref>
<ref id="B128-genes-08-00339">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raho</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Barone</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Philipson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sorrentino</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The gas 5 gene shows four alternative splicing patterns without coding for a protein</article-title>
<source/>Gene
          <year>2000</year>
<volume>256</volume>
<fpage>13</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/S0378-1119(00)00363-2</pub-id>
<pub-id pub-id-type="pmid">11054530</pub-id>
</element-citation>
</ref>
<ref id="B129-genes-08-00339">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e73991</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0073991</pub-id>
<pub-id pub-id-type="pmid">24069260</pub-id>
</element-citation>
</ref>
<ref id="B130-genes-08-00339">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mourtada-Maarabouni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pickard</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Hedge</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Farzaneh</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>G.T.</given-names>
</name>
</person-group>
<article-title>GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer</article-title>
<source/>Oncogene
          <year>2009</year>
<volume>28</volume>
<fpage>195</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2008.373</pub-id>
<pub-id pub-id-type="pmid">18836484</pub-id>
</element-citation>
</ref>
<ref id="B131-genes-08-00339">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasmant</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Laurendeau</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Heron</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bieche</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: Identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF</article-title>
<source/>Cancer Res.
          <year>2007</year>
<volume>67</volume>
<fpage>3963</fpage>
<lpage>3969</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2004</pub-id>
<pub-id pub-id-type="pmid">17440112</pub-id>
</element-citation>
</ref>
<ref id="B132-genes-08-00339">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA ANRIL is up-regulated in bladder cancer and regulates bladder cancer cell proliferation and apoptosis through the intrinsic pathway</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2015</year>
<volume>467</volume>
<fpage>223</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2015.10.002</pub-id>
<pub-id pub-id-type="pmid">26449463</pub-id>
</element-citation>
</ref>
<ref id="B133-genes-08-00339">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thrash-Bingham</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Tartof</surname>
<given-names>K.D.</given-names>
</name>
</person-group>
<article-title>aHIF: A natural antisense transcript overexpressed in human renal cancer and during hypoxia</article-title>
<source/>J. Nat. Cancer Inst.
          <year>1999</year>
<volume>91</volume>
<fpage>143</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="doi">10.1093/jnci/91.2.143</pub-id>
<pub-id pub-id-type="pmid">9923855</pub-id>
</element-citation>
</ref>
<ref id="B134-genes-08-00339">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baranello</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bertozzi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fogli</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Pommier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Capranico</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerases II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1-alpha gene locus</article-title>
<source/>Nucleic Acids Res.
          <year>2010</year>
<volume>38</volume>
<fpage>159</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkp817</pub-id>
<pub-id pub-id-type="pmid">19854946</pub-id>
</element-citation>
</ref>
<ref id="B135-genes-08-00339">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertozzi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Iurlaro</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sordet</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Marinello</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zaffaroni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Capranico</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Characterization of novel antisense HIF-1-alpha transcripts in human cancers</article-title>
<source/>Cell Cycle
          <year>2011</year>
<volume>10</volume>
<fpage>3189</fpage>
<lpage>3197</lpage>
<pub-id pub-id-type="doi">10.4161/cc.10.18.17183</pub-id>
<pub-id pub-id-type="pmid">21897117</pub-id>
</element-citation>
</ref>
<ref id="B136-genes-08-00339">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer</article-title>
<source/>Cancer Lett.
          <year>2016</year>
<volume>376</volume>
<fpage>155</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2016.03.037</pub-id>
<pub-id pub-id-type="pmid">27018306</pub-id>
</element-citation>
</ref>
<ref id="B137-genes-08-00339">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rinn</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Kertesz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Squazzo</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Brugmann</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Goodnough</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Helms</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Farnham</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs</article-title>
<source/>Cell
          <year>2007</year>
<volume>129</volume>
<fpage>1311</fpage>
<lpage>1323</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.05.022</pub-id>
<pub-id pub-id-type="pmid">17604720</pub-id>
</element-citation>
</ref>
<ref id="B138-genes-08-00339">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>M.-C.</given-names>
</name>
<name>
<surname>Manor</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mosammaparast</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNA as modular scaffold of histone modification complexes</article-title>
<source/>Science
          <year>2010</year>
<volume>329</volume>
<fpage>689</fpage>
<lpage>693</lpage>
<pub-id pub-id-type="doi">10.1126/science.1192002</pub-id>
<pub-id pub-id-type="pmid">20616235</pub-id>
</element-citation>
</ref>
<ref id="B139-genes-08-00339">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Horlings</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>M.-C.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Argani</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rinn</surname>
<given-names>J.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis</article-title>
<source/>Nature
          <year>2010</year>
<volume>464</volume>
<fpage>1071</fpage>
<lpage>1076</lpage>
<pub-id pub-id-type="doi">10.1038/nature08975</pub-id>
<pub-id pub-id-type="pmid">20393566</pub-id>
</element-citation>
</ref>
<ref id="B140-genes-08-00339">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.Q.</given-names>
</name>
<name>
<surname>Que</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladder cancer</article-title>
<source/>Tumour Biol.
          <year>2014</year>
<volume>35</volume>
<fpage>10249</fpage>
<lpage>10257</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-014-2344-8</pub-id>
<pub-id pub-id-type="pmid">25030736</pub-id>
</element-citation>
</ref>
<ref id="B141-genes-08-00339">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martínez-Fernández</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Feber</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dueñas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Segovia</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rubio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Villacampa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>López-Calderón</surname>
<given-names>F.F.</given-names>
</name>
<name>
<surname>Gómez-Rodríguez</surname>
<given-names>M.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer</article-title>
<source/>Clin. Epigenetics
          <year>2015</year>
<volume>7</volume>
<fpage>109</fpage>
<pub-id pub-id-type="doi">10.1186/s13148-015-0141-x</pub-id>
<pub-id pub-id-type="pmid">26457124</pub-id>
</element-citation>
</ref>
<ref id="B142-genes-08-00339">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA HOTAIR regulates cyclin J via inhibition of microRNA-205 expression in bladder cancer</article-title>
<source/>Cell Death Dis.
          <year>2015</year>
<volume>6</volume>
<fpage>e1907</fpage>
<pub-id pub-id-type="doi">10.1038/cddis.2015.269</pub-id>
<pub-id pub-id-type="pmid">26469956</pub-id>
</element-citation>
</ref>
<ref id="B143-genes-08-00339">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer</article-title>
<source/>J. Exp. Clin. Cancer Res.
          <year>2016</year>
<volume>35</volume>
<fpage>99</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-016-0372-5</pub-id>
<pub-id pub-id-type="pmid">27328915</pub-id>
</element-citation>
</ref>
<ref id="B144-genes-08-00339">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel antisense long noncoding RNA regulates the expression of MDC1 in bladder cancer</article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>484</fpage>
<lpage>493</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.2861</pub-id>
<pub-id pub-id-type="pmid">25514464</pub-id>
</element-citation>
</ref>
<ref id="B145-genes-08-00339">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prensner</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Balbin</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Dhanasekaran</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Laxman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Asangani</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Grasso</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Kominsky</surname>
<given-names>H.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression</article-title>
<source/>Nat. Biotechnol.
          <year>2011</year>
<volume>29</volume>
<fpage>742</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.1914</pub-id>
<pub-id pub-id-type="pmid">21804560</pub-id>
</element-citation>
</ref>
<ref id="B146-genes-08-00339">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ge</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer</article-title>
<source/>Med. Oncol.
          <year>2013</year>
<volume>30</volume>
<fpage>588</fpage>
<pub-id pub-id-type="doi">10.1007/s12032-013-0588-6</pub-id>
<pub-id pub-id-type="pmid">23640607</pub-id>
</element-citation>
</ref>
<ref id="B147-genes-08-00339">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Z.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inducing cell growth arrest and apoptosis by silencing long non-coding RNA PCAT-1 in human bladder cancer</article-title>
<source/>Tumour Biol.
          <year>2015</year>
<volume>36</volume>
<fpage>7685</fpage>
<lpage>7689</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-015-3490-3</pub-id>
<pub-id pub-id-type="pmid">25934337</pub-id>
</element-citation>
</ref>
<ref id="B148-genes-08-00339">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tseng</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Moriarity</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Akiyama</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ronning</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Reuland</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Guenther</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Beadnell</surname>
<given-names>T.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PVT1 dependence in cancer with MYC copy-number increase</article-title>
<source/>Nature
          <year>2014</year>
<volume>512</volume>
<fpage>82</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1038/nature13311</pub-id>
<pub-id pub-id-type="pmid">25043044</pub-id>
</element-citation>
</ref>
<ref id="B149-genes-08-00339">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Stilwell</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Takano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lapuk</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Fridlyand</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>J.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer</article-title>
<source/>Clin. Cancer Res.
          <year>2007</year>
<volume>13</volume>
<fpage>5745</fpage>
<lpage>5755</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2882</pub-id>
<pub-id pub-id-type="pmid">17908964</pub-id>
</element-citation>
</ref>
<ref id="B150-genes-08-00339">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells</article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>41194</fpage>
<lpage>41203</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.5880</pub-id>
<pub-id pub-id-type="pmid">26517688</pub-id>
</element-citation>
</ref>
<ref id="B151-genes-08-00339">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prensner</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Sahu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Asangani</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vergara</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Davicioni</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Erho</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ghadessi</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex</article-title>
<source/>Nat. Genet.
          <year>2013</year>
<volume>45</volume>
<fpage>1392</fpage>
<lpage>1398</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2771</pub-id>
<pub-id pub-id-type="pmid">24076601</pub-id>
</element-citation>
</ref>
<ref id="B152-genes-08-00339">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Nan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Inhibiting malignant phenotypes of the bladder cancer cells by silencing long noncoding RNA SChLAP1</article-title>
<source/>Int. Urol. Nephrol.
          <year>2016</year>
<volume>48</volume>
<fpage>711</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="doi">10.1007/s11255-016-1230-2</pub-id>
<pub-id pub-id-type="pmid">26861061</pub-id>
</element-citation>
</ref>
<ref id="B153-genes-08-00339">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khaitan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dinger</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Mazar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Mattick</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Perera</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion</article-title>
<source/>Cancer Res.
          <year>2011</year>
<volume>71</volume>
<fpage>3852</fpage>
<lpage>3862</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-4460</pub-id>
<pub-id pub-id-type="pmid">21558391</pub-id>
</element-citation>
</ref>
<ref id="B154-genes-08-00339">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X.L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.C.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>J.Q.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X.Y.</given-names>
</name>
</person-group>
<article-title>Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer</article-title>
<source/>Int. J. Clin. Exp. Pathol.
          <year>2015</year>
<volume>8</volume>
<fpage>1954</fpage>
<lpage>1960</lpage>
<pub-id pub-id-type="pmid">25973088</pub-id>
</element-citation>
</ref>
<ref id="B155-genes-08-00339">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beltran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Puig</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Peña</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>García</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Peña</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bonilla</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>de Herreros</surname>
<given-names>A.G.</given-names>
</name>
</person-group>
<article-title>A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition</article-title>
<source/>Genes Dev.
          <year>2008</year>
<volume>22</volume>
<fpage>756</fpage>
<lpage>769</lpage>
<pub-id pub-id-type="doi">10.1101/gad.455708</pub-id>
<pub-id pub-id-type="pmid">18347095</pub-id>
</element-citation>
</ref>
<ref id="B156-genes-08-00339">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>TGFβ1 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT</article-title>
<source/>Sci. Rep.
          <year>2015</year>
<volume>5</volume>
<fpage>11924</fpage>
<pub-id pub-id-type="doi">10.1038/srep11924</pub-id>
<pub-id pub-id-type="pmid">26152796</pub-id>
</element-citation>
</ref>
<ref id="B157-genes-08-00339">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katzman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Bejerano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fewell</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fulton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Salama</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Haussler</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Human genome ultraconserved elements are ultraselected</article-title>
<source/>Science
          <year>2007</year>
<volume>317</volume>
<fpage>915</fpage>
<pub-id pub-id-type="doi">10.1126/science.1142430</pub-id>
<pub-id pub-id-type="pmid">17702936</pub-id>
</element-citation>
</ref>
<ref id="B158-genes-08-00339">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reneker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lyons</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Pires</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Freeling</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shyu</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Korkin</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Long identical multispecies elements in plant and animal genomes</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2012</year>
<volume>109</volume>
<fpage>E1183</fpage>
<lpage>E1191</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1121356109</pub-id>
<pub-id pub-id-type="pmid">22496592</pub-id>
</element-citation>
</ref>
<ref id="B159-genes-08-00339">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bejerano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pheasant</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Makunin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Stephen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kent</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Mattick</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Haussler</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Ultraconserved elements in the human genome</article-title>
<source/>Science
          <year>2004</year>
<volume>304</volume>
<fpage>1321</fpage>
<lpage>1325</lpage>
<pub-id pub-id-type="doi">10.1126/science.1098119</pub-id>
<pub-id pub-id-type="pmid">15131266</pub-id>
</element-citation>
</ref>
<ref id="B160-genes-08-00339">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCole</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Fonseka</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Koren</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells</article-title>
<source/>PLoS Genet.
          <year>2014</year>
<volume>10</volume>
<elocation-id>e1004646</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1004646</pub-id>
<pub-id pub-id-type="pmid">25340765</pub-id>
</element-citation>
</ref>
<ref id="B161-genes-08-00339">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>The long non-coding RNA NEAT1 interacted with miR-101 modulates breast cancer growth by targeting EZH2</article-title>
<source/>Arch. Biochem. Biophys.
          <year>2017</year>
<volume>615</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.abb.2016.12.011</pub-id>
<pub-id pub-id-type="pmid">28034643</pub-id>
</element-citation>
</ref>
<ref id="B162-genes-08-00339">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ke</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>NEAT1 is required for survival of breast cancer cells through FUS and miR-548</article-title>
<source/>Gene Regul. Syst. Biol.
          <year>2016</year>
<volume>10</volume>
<fpage>11</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.4137/GRSB.S29414</pub-id>
<pub-id pub-id-type="pmid">27147820</pub-id>
</element-citation>
</ref>
<ref id="B163-genes-08-00339">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Promoting progression and clinicopathological significance of NEAT1 over-expression in bladder cancer</article-title>
<source/>Oncotarget. Advance Publications
          <year>2016</year>
<pub-id pub-id-type="doi">10.18632/oncotarget.10084</pub-id>
</element-citation>
</ref>
<ref id="B164-genes-08-00339">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Knockdown of a novel lincRNA AATBC suppresses proliferation and induces apoptosis in bladder cancer</article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>1064</fpage>
<lpage>1078</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.2833</pub-id>
<pub-id pub-id-type="pmid">25473900</pub-id>
</element-citation>
</ref>
<ref id="B165-genes-08-00339">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sha</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of long noncoding RNA lncRNA-n336928 is correlated with tumor stage and grade and overall survival in bladder cancer</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2015</year>
<volume>468</volume>
<fpage>666</fpage>
<lpage>670</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2015.11.013</pub-id>
<pub-id pub-id-type="pmid">26551459</pub-id>
</element-citation>
</ref>
<ref id="B166-genes-08-00339">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>lncRNA up-regulated in nonmuscle invasive bladder cancer facilitates tumor growth and acts as a negative prognostic factor of recurrence</article-title>
<source/>J. Urol.
          <year>2016</year>
<volume>196</volume>
<fpage>1270</fpage>
<lpage>1278</lpage>
<pub-id pub-id-type="doi">10.1016/j.juro.2016.05.107</pub-id>
<pub-id pub-id-type="pmid">27267320</pub-id>
</element-citation>
</ref>
<ref id="B167-genes-08-00339">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peter</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Borkowska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Drayton</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Rakhit</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Noon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Catto</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Identification of differentially expressed long noncoding RNAs in bladder cancer</article-title>
<source/>Clin. Cancer. Res.
          <year>2014</year>
<volume>20</volume>
<fpage>5311</fpage>
<lpage>5321</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0706</pub-id>
<pub-id pub-id-type="pmid">25165097</pub-id>
</element-citation>
</ref>
<ref id="B168-genes-08-00339">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide screening and identification of long noncoding RNAs and their interaction with protein coding RNAs in bladder urothelial cell carcinoma</article-title>
<source/>Cancer Lett.
          <year>2014</year>
<volume>349</volume>
<fpage>77</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2014.03.033</pub-id>
<pub-id pub-id-type="pmid">24705305</pub-id>
</element-citation>
</ref>
<ref id="B169-genes-08-00339">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartel</surname>
<given-names>D.P.</given-names>
</name>
</person-group>
<article-title>MicroRNAs: Genomics, biogenesis, mechanism, and function</article-title>
<source/>Cell
          <year>2004</year>
<volume>116</volume>
<fpage>281</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(04)00045-5</pub-id>
<pub-id pub-id-type="pmid">14744438</pub-id>
</element-citation>
</ref>
<ref id="B170-genes-08-00339">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>International Human Genome Sequencing Consortium</collab>
</person-group>
<article-title>Finishing the euchromatic sequence of the human genome</article-title>
<source/>Nature
          <year>2004</year>
<volume>431</volume>
<fpage>931</fpage>
<lpage>945</lpage>
<pub-id pub-id-type="pmid">15496913</pub-id>
</element-citation>
</ref>
<ref id="B171-genes-08-00339">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huttenhofer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schattner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Polacek</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Non-coding RNAs: Hope or hype?</article-title>
<source/>Trends Genet.
          <year>2005</year>
<volume>21</volume>
<fpage>289</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1016/j.tig.2005.03.007</pub-id>
<pub-id pub-id-type="pmid">15851066</pub-id>
</element-citation>
</ref>
<ref id="B172-genes-08-00339">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Naoe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Akao</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Identification of non-coding RNAs embracing microRNA-143/145 cluster</article-title>
<source/>Mol. Cancer
          <year>2010</year>
<volume>9</volume>
<fpage>136</fpage>
<pub-id pub-id-type="doi">10.1186/1476-4598-9-136</pub-id>
<pub-id pub-id-type="pmid">20525177</pub-id>
</element-citation>
</ref>
<ref id="B173-genes-08-00339">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enokida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matsushita</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The role of microRNAs in bladder cancer</article-title>
<source/>Investig. Clin. Urol.
          <year>2016</year>
<volume>57</volume>
<fpage>S60</fpage>
<lpage>S76</lpage>
<pub-id pub-id-type="doi">10.4111/icu.2016.57.S1.S60</pub-id>
<pub-id pub-id-type="pmid">27326409</pub-id>
</element-citation>
</ref>
<ref id="B174-genes-08-00339">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>E.C.</given-names>
</name>
</person-group>
<article-title>Complementary miRNA pairs suggest a regulatory role for miRNA:miRNA duplexes</article-title>
<source/>RNA
          <year>2004</year>
<volume>10</volume>
<fpage>171</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1261/rna.5191904</pub-id>
<pub-id pub-id-type="pmid">14730015</pub-id>
</element-citation>
</ref>
<ref id="B175-genes-08-00339">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartel</surname>
<given-names>D.P.</given-names>
</name>
</person-group>
<article-title>MicroRNAs: Target recognition and regulatory functions</article-title>
<source/>Cell
          <year>2009</year>
<volume>136</volume>
<fpage>215</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.01.002</pub-id>
<pub-id pub-id-type="pmid">19167326</pub-id>
</element-citation>
</ref>
<ref id="B176-genes-08-00339">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moldovan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Batte</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Trgovcich</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wisler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Piper</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Methodological challenges in utilizing miRNA as circulating biomarkers</article-title>
<source/>J. Cell. Mol. Med.
          <year>2014</year>
<volume>18</volume>
<fpage>371</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1111/jcmm.12236</pub-id>
<pub-id pub-id-type="pmid">24533657</pub-id>
</element-citation>
</ref>
<ref id="B177-genes-08-00339">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christopher</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bansal</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>MicroRNA therapeutics: Discovering novel targets and developing specific therapy</article-title>
<source/>Perspect. Clin. Res.
          <year>2016</year>
<volume>7</volume>
<fpage>68</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.4103/2229-3485.179431</pub-id>
<pub-id pub-id-type="pmid">27141472</pub-id>
</element-citation>
</ref>
<ref id="B178-genes-08-00339">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matullo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Naccarati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pardini</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>MicroRNA expression profiling in bladder cancer: The challenge of next-generation sequencing in tissues and biofluids</article-title>
<source/>Int. J. Cancer
          <year>2016</year>
<volume>138</volume>
<fpage>2334</fpage>
<lpage>2345</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.29895</pub-id>
<pub-id pub-id-type="pmid">26489968</pub-id>
</element-citation>
</ref>
<ref id="B179-genes-08-00339">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A systematic analysis on DNA methylation and the expression of both mRNA and microRNA in bladder cancer</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<elocation-id>e28223</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0028223</pub-id>
<pub-id pub-id-type="pmid">22140553</pub-id>
</element-citation>
</ref>
<ref id="B180-genes-08-00339">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.Q.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.Z.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of microRNAs expression profiling in one group of Chinese urothelial cell carcinoma identified by Solexa sequencing</article-title>
<source/>Urol. Oncol.
          <year>2013</year>
<volume>31</volume>
<fpage>219</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/j.urolonc.2010.11.007</pub-id>
<pub-id pub-id-type="pmid">21795071</pub-id>
</element-citation>
</ref>
<ref id="B181-genes-08-00339">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zabolotneva</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Zhavoronkov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garazha</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Roumiantsev</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Buzdin</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>Characteristic patterns of microRNA expression in human bladder cancer</article-title>
<source/>Front. Genet.
          <year>2013</year>
<volume>3</volume>
<fpage>310</fpage>
<pub-id pub-id-type="doi">10.3389/fgene.2012.00310</pub-id>
<pub-id pub-id-type="pmid">23316212</pub-id>
</element-citation>
</ref>
<ref id="B182-genes-08-00339">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itesako</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Seki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chiyomaru</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hidaka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yonezawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nohata</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The microRNA expression signature of bladder cancer by deep sequencing: The functional significance of the miR-195/497 cluster</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<elocation-id>e84311</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0084311</pub-id>
<pub-id pub-id-type="pmid">24520312</pub-id>
</element-citation>
</ref>
<ref id="B183-genes-08-00339">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Dysregulation of miRNA in bladder cancer: Altered expression with aberrant biogenesis procedure</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>27547</fpage>
<lpage>27568</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.15173</pub-id>
<pub-id pub-id-type="pmid">28187437</pub-id>
</element-citation>
</ref>
<ref id="B184-genes-08-00339">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitash</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Agnihotri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mandhani</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Bladder cancer: Micro RNAs as biomolecules for prognostication and surveillance</article-title>
<source/>Indian J. Urol.
          <year>2017</year>
<volume>33</volume>
<fpage>127</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.4103/0970-1591.203412</pub-id>
<pub-id pub-id-type="pmid">28469300</pub-id>
</element-citation>
</ref>
<ref id="B185-genes-08-00339">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MicroRNAs with prognostic significance in bladder cancer: A systematic review and meta-analysis</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>5619</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-05801-3</pub-id>
<pub-id pub-id-type="pmid">28717125</pub-id>
</element-citation>
</ref>
<ref id="B186-genes-08-00339">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ichimi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Enokida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Okuno</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kunimoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chiyomaru</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Toki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of novel microRNA targets based on microRNA signatures in bladder cancer</article-title>
<source/>Int. J. Cancer
          <year>2009</year>
<volume>125</volume>
<fpage>345</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.24390</pub-id>
<pub-id pub-id-type="pmid">19378336</pub-id>
</element-citation>
</ref>
<ref id="B187-genes-08-00339">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Seki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Matsushita</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yonemori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Enokida</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer</article-title>
<source/>Br. J. Cancer
          <year>2016</year>
<volume>115</volume>
<fpage>354</fpage>
<lpage>363</lpage>
<pub-id pub-id-type="doi">10.1038/bjc.2016.179</pub-id>
<pub-id pub-id-type="pmid">27310702</pub-id>
</element-citation>
</ref>
<ref id="B188-genes-08-00339">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Homami</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghazi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>MicroRNAs as biomarkers associated with bladder cancer</article-title>
<source/>Med. J. Islam. Repub. Iran
          <year>2016</year>
<volume>30</volume>
<fpage>475</fpage>
<pub-id pub-id-type="pmid">28491850</pub-id>
</element-citation>
</ref>
<ref id="B189-genes-08-00339">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guancial</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bellmunt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bamias</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Choueiri</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schutz</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>M.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder</article-title>
<source/>Cancer Med.
          <year>2014</year>
<volume>3</volume>
<fpage>835</fpage>
<lpage>844</lpage>
<pub-id pub-id-type="doi">10.1002/cam4.262</pub-id>
<pub-id pub-id-type="pmid">24846059</pub-id>
</element-citation>
</ref>
<ref id="B190-genes-08-00339">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Junker</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>van Oers</surname>
<given-names>J.M.M.</given-names>
</name>
<name>
<surname>Zwarthoff</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Kania</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations</article-title>
<source/>Neoplasia
          <year>2008</year>
<volume>10</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1593/neo.07178</pub-id>
<pub-id pub-id-type="pmid">18231634</pub-id>
</element-citation>
</ref>
<ref id="B191-genes-08-00339">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Theodorescu</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)</article-title>
<source/>Expert Rev. Mol. Med.
          <year>2010</year>
<volume>12</volume>
<fpage>e10</fpage>
<pub-id pub-id-type="doi">10.1017/S1462399410001407</pub-id>
<pub-id pub-id-type="pmid">20334706</pub-id>
</element-citation>
</ref>
<ref id="B192-genes-08-00339">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cappellen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ricol</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>de Medina</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bourdin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sastre-Garau</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chopin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thiery</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Radvanyi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Frequent activating mutations of <italic>FGFR3</italic> in human bladder and cervix carcinomas</article-title>
<source/>Nat. Genet.
          <year>1999</year>
<volume>23</volume>
<fpage>18</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1038/12615</pub-id>
<pub-id pub-id-type="pmid">10471491</pub-id>
</element-citation>
</ref>
<ref id="B193-genes-08-00339">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sibley</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours</article-title>
<source/>Oncogene
          <year>2001</year>
<volume>20</volume>
<fpage>4416</fpage>
<lpage>4418</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1204543</pub-id>
<pub-id pub-id-type="pmid">11466624</pub-id>
</element-citation>
</ref>
<ref id="B194-genes-08-00339">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morais</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Viana</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Piantino</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Massoco</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moura</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dip</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Srougi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leite</surname>
<given-names>K.R.</given-names>
</name>
</person-group>
<article-title>The involvement of miR-100 in bladder urothelial carcinogenesis changing the expression levels of mRNA and proteins of genes related to cell proliferation, survival, apoptosis and chromosomal stability</article-title>
<source/>Cancer Cell Int.
          <year>2014</year>
<volume>14</volume>
<fpage>119</fpage>
<pub-id pub-id-type="doi">10.1186/s12935-014-0119-3</pub-id>
<pub-id pub-id-type="pmid">25493074</pub-id>
</element-citation>
</ref>
<ref id="B195-genes-08-00339">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer</article-title>
<source/>Clin. Transl. Oncol.
          <year>2013</year>
<volume>15</volume>
<fpage>849</fpage>
<lpage>854</lpage>
<pub-id pub-id-type="doi">10.1007/s12094-013-1014-4</pub-id>
<pub-id pub-id-type="pmid">23408039</pub-id>
</element-citation>
</ref>
<ref id="B196-genes-08-00339">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catto</surname>
<given-names>J.W.F.</given-names>
</name>
<name>
<surname>Miah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Bryant</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dudziec</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Larré</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Milo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rehman</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rosario</surname>
<given-names>D.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distinct microRNA alterations characterize high- and low-grade bladder cancer</article-title>
<source/>Cancer Res.
          <year>2009</year>
<volume>69</volume>
<fpage>8472</fpage>
<lpage>8481</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0744</pub-id>
<pub-id pub-id-type="pmid">19843843</pub-id>
</element-citation>
</ref>
<ref id="B197-genes-08-00339">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veerla</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lindgren</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kvist</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Frigyesi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Staaf</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Persson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liedberg</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chebil</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gudjonsson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Borg</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31</article-title>
<source/>Int. J. Cancer
          <year>2009</year>
<volume>124</volume>
<fpage>2236</fpage>
<lpage>2242</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.24183</pub-id>
<pub-id pub-id-type="pmid">19127597</pub-id>
</element-citation>
</ref>
<ref id="B198-genes-08-00339">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourdon</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>p53 and its isoforms in cancer</article-title>
<source/>Br. J. Cancer
          <year>2007</year>
<volume>97</volume>
<fpage>277</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6603886</pub-id>
<pub-id pub-id-type="pmid">17637683</pub-id>
</element-citation>
</ref>
<ref id="B199-genes-08-00339">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>P.A.J.</given-names>
</name>
<name>
<surname>Vousden</surname>
<given-names>K.H.</given-names>
</name>
</person-group>
<article-title>Mutant p53 in cancer: New functions and therapeutic opportunities</article-title>
<source/>Cancer Cell
          <year>2014</year>
<volume>25</volume>
<fpage>304</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1016/j.ccr.2014.01.021</pub-id>
<pub-id pub-id-type="pmid">24651012</pub-id>
</element-citation>
</ref>
<ref id="B200-genes-08-00339">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rivlin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Brosh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Oren</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rotter</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis</article-title>
<source/>Genes Cancer
          <year>2011</year>
<volume>2</volume>
<fpage>466</fpage>
<lpage>474</lpage>
<pub-id pub-id-type="doi">10.1177/1947601911408889</pub-id>
<pub-id pub-id-type="pmid">21779514</pub-id>
</element-citation>
</ref>
<ref id="B201-genes-08-00339">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smal</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Rolevich</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Polyakov</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Krasny</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Goncharova</surname>
<given-names>R.I.</given-names>
</name>
</person-group>
<article-title><italic>FGFR3</italic> and <italic>TP53</italic> mutations in a prospective cohort of Belarusian bladder cancer patients</article-title>
<source/>Exp. Oncol.
          <year>2014</year>
<volume>36</volume>
<fpage>246</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">25537218</pub-id>
</element-citation>
</ref>
<ref id="B202-genes-08-00339">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porrello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Soddu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zbilut</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Crescenzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giuliani</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Discrimination of single amino acid mutations of the p53 protein by means of deterministic singularities of recurrence quantification analysis</article-title>
<source/>Proteins
          <year>2004</year>
<volume>55</volume>
<fpage>743</fpage>
<lpage>755</lpage>
<pub-id pub-id-type="doi">10.1002/prot.20075</pub-id>
<pub-id pub-id-type="pmid">15103636</pub-id>
</element-citation>
</ref>
<ref id="B203-genes-08-00339">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ano Bom</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Rangel</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Sanches</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Braga</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Gava</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Cepeda</surname>
<given-names>A.O.</given-names>
</name>
<name>
<surname>Stumbo</surname>
<given-names>A.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: Implications for cancer</article-title>
<source/>J. Biol. Chem.
          <year>2012</year>
<volume>287</volume>
<fpage>28152</fpage>
<lpage>28162</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.340638</pub-id>
<pub-id pub-id-type="pmid">22715097</pub-id>
</element-citation>
</ref>
<ref id="B204-genes-08-00339">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Salot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sengupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Navalkar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jha</surname>
<given-names>N.N.</given-names>
</name>
<name>
<surname>Sahay</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>p53 amyloid formation leading to its loss of function: Implications in cancer pathogenesis</article-title>
<source/>Cell Death Differ.
          <year>2017</year>
<pub-id pub-id-type="doi">10.1038/cdd.2017.105</pub-id>
<pub-id pub-id-type="pmid">28644435</pub-id>
</element-citation>
</ref>
<ref id="B205-genes-08-00339">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vosgha</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Salajegheh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>The important roles of miR-205 in normal physiology, cancers and as a potential therapeutic target</article-title>
<source/>Curr. Cancer Drug Targets
          <year>2014</year>
<volume>14</volume>
<fpage>621</fpage>
<lpage>637</lpage>
<pub-id pub-id-type="doi">10.2174/156800961407140926105634</pub-id>
<pub-id pub-id-type="pmid">25308719</pub-id>
</element-citation>
</ref>
<ref id="B206-genes-08-00339">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neely</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Rieger-Christ</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Neto</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Eroshkin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garver</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Phung</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Libertino</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Whitney</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A microRNA expression ratio defining the invasive phenotype in bladder tumors</article-title>
<source/>Urol. Oncol.
          <year>2010</year>
<volume>28</volume>
<fpage>39</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1016/j.urolonc.2008.06.006</pub-id>
<pub-id pub-id-type="pmid">18799331</pub-id>
</element-citation>
</ref>
<ref id="B207-genes-08-00339">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catto</surname>
<given-names>J.W.F.</given-names>
</name>
<name>
<surname>Alcaraz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bjartell</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>de Vere White</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Fussel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hamdy</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Kallioniemi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mengual</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schlomm</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MicroRNA in prostate, bladder, and kidney cancer: A systematic review</article-title>
<source/>Eur. Urol.
          <year>2011</year>
<volume>59</volume>
<fpage>671</fpage>
<lpage>681</lpage>
<pub-id pub-id-type="doi">10.1016/j.eururo.2011.01.044</pub-id>
<pub-id pub-id-type="pmid">21296484</pub-id>
</element-citation>
</ref>
<ref id="B208-genes-08-00339">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalmay</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>MicroRNAs and the hallmarks of cancer</article-title>
<source/>Oncogene
          <year>2006</year>
<volume>25</volume>
<fpage>6170</fpage>
<lpage>6175</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1209911</pub-id>
<pub-id pub-id-type="pmid">17028596</pub-id>
</element-citation>
</ref>
<ref id="B209-genes-08-00339">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guancial</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Bellmunt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>The evolving understanding of microRNA in bladder cancer</article-title>
<source/>Urol. Oncol.
          <year>2014</year>
<volume>32</volume>
<fpage>41.e31</fpage>
<lpage>41.e40</lpage>
<pub-id pub-id-type="doi">10.1016/j.urolonc.2013.04.014</pub-id>
<pub-id pub-id-type="pmid">23911686</pub-id>
</element-citation>
</ref>
<ref id="B210-genes-08-00339">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Diverse functions of miR-373 in cancer</article-title>
<source/>J. Transl. Med.
          <year>2015</year>
<volume>13</volume>
<fpage>162</fpage>
<pub-id pub-id-type="doi">10.1186/s12967-015-0523-z</pub-id>
<pub-id pub-id-type="pmid">25990556</pub-id>
</element-citation>
</ref>
<ref id="B211-genes-08-00339">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boominathan</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e10615</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0010615</pub-id>
<pub-id pub-id-type="pmid">20485546</pub-id>
</element-citation>
</ref>
<ref id="B212-genes-08-00339">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y.-J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.-J.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>E.Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kwak</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN modulates miR-21 processing via RNA-regulatory protein RNH1</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<elocation-id>e28308</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0028308</pub-id>
<pub-id pub-id-type="pmid">22162762</pub-id>
</element-citation>
</ref>
<ref id="B213-genes-08-00339">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Rhijn</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>van der Kwast</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Vis</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Kirkels</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Boevé</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Jöbsis</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Zwarthoff</surname>
<given-names>E.C.</given-names>
</name>
</person-group>
<article-title>FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma</article-title>
<source/>Cancer Res.
          <year>2004</year>
<volume>64</volume>
<fpage>1911</fpage>
<lpage>1914</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-2421</pub-id>
<pub-id pub-id-type="pmid">15026322</pub-id>
</element-citation>
</ref>
<ref id="B214-genes-08-00339">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hoefig</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Merz</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Feller</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Kausch</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Jocham</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Warnecke</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Sczakiel</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>A robust methodology to study urine microRNA as tumor marker: MicroRNA-126 and microRNA-182 are related to urinary bladder cancer</article-title>
<source/>Urol. Oncol.
          <year>2010</year>
<volume>28</volume>
<fpage>655</fpage>
<lpage>661</lpage>
<pub-id pub-id-type="doi">10.1016/j.urolonc.2009.01.027</pub-id>
<pub-id pub-id-type="pmid">19375957</pub-id>
</element-citation>
</ref>
<ref id="B215-genes-08-00339">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Evaluation of miR-182/miR-100 ratio for diagnosis and survival prediction in bladder cancer</article-title>
<source/>Arch. Iran. Med.
          <year>2016</year>
<volume>19</volume>
<fpage>645</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="pmid">27631180</pub-id>
</element-citation>
</ref>
<ref id="B216-genes-08-00339">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christov</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Gardiner</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Szuts</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Krude</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Functional requirement of noncoding Y RNAs for human chromosomal DNA replication</article-title>
<source/>Mol. Cell. Biol.
          <year>2006</year>
<volume>26</volume>
<fpage>6993</fpage>
<lpage>7004</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01060-06</pub-id>
<pub-id pub-id-type="pmid">16943439</pub-id>
</element-citation>
</ref>
<ref id="B217-genes-08-00339">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christov</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Trivier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Krude</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Noncoding human Y RNAs are overexpressed in tumours and required for cell proliferation</article-title>
<source/>Br. J. Cancer
          <year>2008</year>
<volume>98</volume>
<fpage>981</fpage>
<lpage>988</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6604254</pub-id>
<pub-id pub-id-type="pmid">18283318</pub-id>
</element-citation>
</ref>
<ref id="B218-genes-08-00339">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kowalski</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Krude</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Functional roles of non-coding Y RNAs</article-title>
<source/>Int. J. Biochem. Cell Biol.
          <year>2015</year>
<volume>66</volume>
<fpage>20</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2015.07.003</pub-id>
<pub-id pub-id-type="pmid">26159929</pub-id>
</element-citation>
</ref>
<ref id="B219-genes-08-00339">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>Y.N.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>S.Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Circular RNAs: A novel type of biomarker and genetic tools in cancer</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>64551</fpage>
<lpage>64563</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.18350</pub-id>
<pub-id pub-id-type="pmid">28969093</pub-id>
</element-citation>
</ref>
<ref id="B220-genes-08-00339">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Circular RNAs in cancer: An emerging key player</article-title>
<source/>J. Hematol. Oncol.
          <year>2017</year>
<volume>10</volume>
<fpage>2</fpage>
<pub-id pub-id-type="doi">10.1186/s13045-016-0370-2</pub-id>
<pub-id pub-id-type="pmid">28049499</pub-id>
</element-citation>
</ref>
<ref id="B221-genes-08-00339">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Screening differential circular RNA expression profiles reveals the regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in bladder carcinoma</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>30919</fpage>
<pub-id pub-id-type="doi">10.1038/srep30919</pub-id>
<pub-id pub-id-type="pmid">27484176</pub-id>
</element-citation>
</ref>
<ref id="B222-genes-08-00339">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway</article-title>
<source/>Cancer Lett.
          <year>2017</year>
<volume>403</volume>
<fpage>305</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2017.06.027</pub-id>
<pub-id pub-id-type="pmid">28687357</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="genes-08-00339-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Classification of long non-coding RNA (lncRNA) and micro-RNA (miR) involved in bladder cancer (BC) etiology based on their regulation. (<bold>A</bold>) lncRNA classes according to their levels of expression in BC vs. normal urothelium. lncRNA are divided into two classes: (i) lncRNA that are up-regulated (in red; 24/32); and (ii) lncRNA that are down-regulated (in green; 8/32). To date, BC-related lncRNA have been univocally described as up- or downregulated. (<bold>B</bold>) miR classes according to their levels of expression in BC vs. normal urothelium. miR are split into three classes: (i) miR that are upregulated (in red; 16/65); (ii) miR that are downregulated (in green; 44/65); and (iii) miR that have been described both as up- and downregulated and, as such, cannot be univocally classified using the available data (in grey; 5/65). Notably, while 75% of the BC-related lncRNA are upregulated (i.e., they act as oncogenes), more than 70% of these miR are potentially downregulated (considering all downregulated and half of the non-univocally classified miR), i.e., act as tumor suppressors.</p>
</caption>
<graphic xlink:href="genes-08-00339-g001"></graphic>
</fig>
<table-wrap id="genes-08-00339-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">genes-08-00339-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Main non-coding RNA (ncRNA) classes, listed according to increasing length (in nucleotides (nt)).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Name</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Acronym</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Length (nt)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Notes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Long non-coding RNAs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lncRNA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">&gt;200</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Non-protein coding transcripts; heterogeneous class of RNAs</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B41-genes-08-00339">41</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transcribed ultraconserved region</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">T-UCR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">≈50–570</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Frequently located at fragile sites and cancer-associated genomic regions; possibly regulated by miR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B42-genes-08-00339">42</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Circular RNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">circRNA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">≈100–1600</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Covalently closed RNA rings; some have coding functions; potential gene regulators and miR “traps”</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B43-genes-08-00339">43</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Small interfering RNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">siRNA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">20–25</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Double-stranded RNAs similar to miR, operating through RNA interference (RNAi) pathway; promote mRNA degradation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B44-genes-08-00339">44</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Y RNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Y RNA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">21–24</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Necessary for DNA replication through interactions with chromatin and initiation proteins; target of autoimmune antibodies</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B45-genes-08-00339">45</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Micro-RNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miRNA; miR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">21–24</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Function in RNA silencing and post-transcriptional regulation of gene expression; may have an extracellular localization</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B46-genes-08-00339">46</xref>,<xref ref-type="bibr" rid="B47-genes-08-00339">47</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Piwi-interacting RNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">piRNA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">26–31</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Epigenetic and post-transcriptional gene silencing of retrotransposons and other genetic elements in germ line cells</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B48-genes-08-00339">48</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Small nucleolar RNAs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">snoRNAs</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">60–300</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Guide chemical modifications of other RNAs (rRNA, tRNA, snRNA)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B49-genes-08-00339">49</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Small nuclear ribonucleic acid</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">snRNA; U-RNA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">≈150</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Function in the processing of pre-messenger RNA (hnRNA) in the nucleus; aid in the regulation of transcription factors; telomere maintenance</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B50-genes-08-00339">50</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="genes-08-00339-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">genes-08-00339-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Synopsis of the lncRNA with a role in BC formation. These lncRNA were collected either performing a keyword-based PubMed search or from the database Lnc2Cancer; additional information was retrieved from the original papers or from the GeneCards [<xref ref-type="bibr" rid="B58-genes-08-00339">58</xref>] and OMIM [<xref ref-type="bibr" rid="B59-genes-08-00339">59</xref>] databases.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Name</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Acronym</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Map</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Approx. Length in Kb</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Regulation in BC</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Urothelial cancer-associated 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">UCA1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">19p13.12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell cycle regulation, cell proliferation, cell migration, cell invasion, apoptosis inhibition</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Metastasis-associated lung adenocarcinoma transcript 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MALAT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11q13.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Alternative splicing, nuclear organization, modulation of gene expression</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Imprinted maternally expressed noncoding transcript H19</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">H19</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11p15.5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Modulation of gene expression pre- and post-translation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Taurine Upregulated Gene 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TUG1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">22q12.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3.3, 5.9, 6.4, 9.7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation and migration</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Maternally expressed gene 3</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MEG3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14q32.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.6 plus other putative sizes</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Maternally imprinted gene, chromatin function, angiogenesis, autophagy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MiR-31 host gene</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MIR31HG</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9p21.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gene expression through DNA methylation, chromatin structure</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Long intergenic noncoding RNA upregulated in bladder cancer 1; Bladder Cancer Associated Transcript 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Linc-UBC1, BLACAT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1q32.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, cell motility, invasiveness, colony formation, chromatin structure</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LOC572558</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LOC572558</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9q13</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, cell motility</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Promoter of CDKN1A antisense DNA damage-activated RNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PANDAR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6p21.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Apoptotic response to DNA damage</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gastric carcinoma high expressed transcript 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GHET1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7q36.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, cell invasion, EMT (epithelial to mesenchymal transition)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Non-coding RNA expressed in aggressive neuroblastoma</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ncRAN</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17q25.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.1, 2.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, cell migration, cell invasion, chemotherapy resistance</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Growth-arrest-specific transcript 5</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GAS5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1q25.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.67 (exons only)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell division through <italic>CDK6</italic> (cyclin dependent kinase 6) control</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Antisense noncoding RNA in the INK4 locus</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ANRIL, CDKN2B-AS1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9p21.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.7, 3.8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Co-expressed with <italic>CDKN2A</italic> (cyclin dependent kinase inhibitor 2A); cell proliferation and apoptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hypoxia inducible factor 1 alpha antisense RNA-2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HIF1A-AS2, aHIF</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14q23.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, cell migration, apoptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HOX transcript antisense RNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HOTAIR, HOXAS</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12q13.13</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Regulation of cyclin J via inhibition of miR-205</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HOXD antisense growth-associated long non-coding RNA, HOXD cluster antisense RNA 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HAGLR, HOXD-AS1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2q31.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15.8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Regulation of tumor size, histological grade and TNM (tumor-node-metastasis) stage</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mediator of DNA damage checkpoint protein 1 antisense RNA 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MDC1-AS1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6p21.33</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DNA damage checkpoint, apoptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Prostate cancer associated transcript 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PCAT-1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8q24.21</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, apoptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Plasmacytoma variant translocation 1 (Pvt1) Oncogene</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PVT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8q24.21</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Co-expression with <italic>MYC</italic> (myelocytomatosis viral oncogene homolog), cell proliferation, apoptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SWI/SNF complex antagonist associated with prostate cancer 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SChLAP1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2q31.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.7, 1.4, 1.3, 1.1 (major forms)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, apoptosis, cell migration</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SPRY4 intronic transcript 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SPRY4-IT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5q31.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, cell migration, cell invasion</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ZEB2 Antisense RNA 1, Zeb2 natural antisense transcript</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ZEB2-AS1, ZEB2NAT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2q22.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TGFβ1 (transforming growth factor beta 1) signaling and epithelial to mesenchymal transition (EMT) control</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ultraconserved RNA 8+, translated ultraconserved region 8+</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">uc.8+, T-UCR 8+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1p36.22</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Interaction with miR-596; cell invasion, migration, and proliferation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nuclear enriched abundant transcript 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">NEAT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11q13.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, miR-101 interaction</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Apoptosis associated transcript in bladder cancer</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AATBC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">21q22.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4.6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, apoptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LncRNA-n336928</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lncRNA-n336928</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up-regulated in non-muscle invasive bladder cancer</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lncRNA-UNMIBC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tumor relapse, chromatin structure</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tenascin XA pseudogene</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TNXA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6p21.33</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4.6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CADM3 antisense RNA 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CADM3-AS1, CTA-134P22.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1q23.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">n/a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C5orf66 antisense RNA 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C5orf66-AS1, CTC-276P9.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5q31.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Keratin 19 pseudogene 3</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">KRT19P3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4q25</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AB074278</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AB074278</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17q23.2-23.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Possible functional interactions with TANC2 (tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2) and EMP1 (epithelial membrane protein 1)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="genes-08-00339-t003" orientation="portrait" position="float">
<object-id pub-id-type="pii">genes-08-00339-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>List of microRNA (miR) with an established role in BC and at least one recognized target gene. miR are ordered according to their first digit, then second digit, and so on; notes are taken from the OMIM database [<xref ref-type="bibr" rid="B59-genes-08-00339">59</xref>] and describe either the molecular or the cellular function of the target gene.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">miR</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Regulation in BC</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Proposed Target Gene</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Notes on Target Gene</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Refs *</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">miR-1</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SRSF9/SRp30c</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Splicing, apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">TAGLN2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuronal protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">LASP1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Oncogene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PNP</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Purine nucleoside phosphorylase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PTMA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hormone polypeptide precursor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">miR-10</td>
<td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RASSF1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell cycle inhibitor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MAPK1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell growth, adhesion, survival, differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PKC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">GRB2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Growth factor-induced activation of RAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ATM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">DNA repair</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MDM2/4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ubiquitin ligase targeting TP53</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-10b</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">HOXD10</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Homeobox, transcription factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">KLF4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-100</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MTOR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Protein kinase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">miR-101</td>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">PLCG</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Actin organization, cell migration</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">EZH2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Histone methyltransferase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">COX2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Inflammation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MET</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Oncogene, growth factor receptor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">VEGFC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Growth factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">miR-103</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">MSK1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PKC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-1182</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TERT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Telomerase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-124-3p</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ROK1/DDX52</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Putative RNA helicase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CDK4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cyclin-dependent kinase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">miR-125</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RAF1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase, oncogene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">KRAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Activation of mitosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CDKN2A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Proliferation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TP53</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Proliferation, apoptosis, angiogenesis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">miR-125b</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">E2F3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MMP13</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Matrix metalloproteinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SPHK1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sphingosine kinase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-128</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">VEGFC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RAS regulator, growth factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">miR-129</td>
<td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">Down or up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GALNT1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Post-transcriptional glycosylation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SOX4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SHC4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Acetylcholine receptor clustering</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PKC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">GRB2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Growth factor-induced activation of RAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MDM4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Ubiquitin ligase targeting TP53</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ATM</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DNA repair</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="8" style="border-bottom:solid thin" valign="middle">miR-133a</td>
<td align="center" colspan="1" rowspan="8" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EGFR</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell proliferation, differentiation, motility, survival</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FSCN1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Actin-bundling</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">GSTP1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Detoxification</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">LASP1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Oncogene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PNP</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Purine nucleoside phosphorylase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PTMA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Hormone polypeptide precursor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">TAGLN2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuronal protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">KRT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Keratin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B186-genes-08-00339">186</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">miR-133b</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">AKT1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Protein kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">BCL2L2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">EGFR</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell proliferation, differentiation, motility, survival</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">KRT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Keratin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B186-genes-08-00339">186</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-135a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FOXO1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell cycle regulation, apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-138</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ZEB2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transcription repression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="11" style="border-bottom:solid thin" valign="middle">miR-143</td>
<td align="center" colspan="1" rowspan="11" style="border-bottom:solid thin" valign="middle">Down or up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ERK5/MAPK7</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">AKT</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PDGFB</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Growth factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PDGRFB</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Inorganic phosphate transporter</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PKC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SOS1/2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Positive regulator of RAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">KRAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Activation of mitosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">RAF1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase, oncogene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ATM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">DNA repair</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">TP53</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Proliferation, apoptosis, angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SERPIN</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Serine proteinase inhibitors</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">miR-144-5p/3p</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CCNE1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cyclin</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CCNE2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cyclin</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CDC25A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Phosphatase, cell cycle</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PKMYT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Membrane-associated cdc2-inhibitory kinase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="11" style="border-bottom:solid thin" valign="middle">miR-145</td>
<td align="center" colspan="1" rowspan="11" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">PKC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CBFB</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CLINT1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Early and recycling endosomes</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FSCN1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Actin-bundling</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ILK</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Protein kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PAK1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Protein kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PPP3CA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Protein phosphatase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SERPIN1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Serine proteinase inhibitors</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SOCS7</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell signaling, cytoskeleton</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">IGF1R</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Growth factor receptor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-150</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PDCD4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tumor suppressor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-152</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DNMT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">miR-155</td>
<td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CASP3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">TP53BP1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SOCS1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytokine response</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PTEN</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tumor suppressor gene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PDCD4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tumor suppressor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SHIP1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DMTF1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-16</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CCND1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cyclin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-182-5p</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RECK</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tumor suppressor, cell shape</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B184-genes-08-00339">184</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SMAD4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Signal transduction of the transforming growth Factor-beta</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B184-genes-08-00339">184</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-186</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HMGN5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nucleosome, transcription activation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">miR-1826</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CTNNB1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Wnt/beta-catenin regulator</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MEK1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RAS regulator</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">VECFG</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RAS regulator, growth factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-19a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PTEN</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tumor suppressor gene</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">miR-193a-3p</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">LOXL4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Extracellular matrix formation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PSEN1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NOTCH receptor cleavage</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HOXC9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Homeobox, transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="11" style="border-bottom:solid thin" valign="middle">miR-195</td>
<td align="center" colspan="1" rowspan="11" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CDK-4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cyclin-dependent kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">RAF1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase, oncogene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MAP2K1/2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase, cell growth</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MAPK1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell growth, adhesion, survival, differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SOS1/2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Positive regulator of RAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">GRB2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Growth factor-induced activation of RAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">BIRC5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CDC42</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GTPase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">GLUT3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Glucose transporter</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">WNT7A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell signaling</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">miR-200b/c</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">Down or up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ERRFI-1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Regulator of EGFR</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ZEB1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Transcriptional repressor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B184-genes-08-00339">184</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MMP16</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Matrix metalloproteinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">BMI1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Oncogene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">E2F3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-203</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">BCL2L2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">BIRC5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">miR-205</td>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">TP53</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Proliferation, apoptosis, angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PTEN</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tumor suppressor gene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">C-ERB-B-3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Receptor tyrosine kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CDC42</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GTPase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">YES</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tyrosine kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ZEB1/2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transcription repression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B184-genes-08-00339">184</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="11" style="border-bottom:solid thin" valign="middle">miR-21</td>
<td align="center" colspan="1" rowspan="11" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">TP53</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Proliferation, apoptosis, angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">TIMP3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Degradation of extracellular matrix</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">BCL2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PTEN</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tumor suppressor gene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">TPM1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tumor suppressor gene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MSH2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">DNA repair</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">E2F3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ATM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">DNA repair</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">VEGFC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Growth factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PDCD4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tumor suppressor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TPM1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tumor suppressor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-210</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">VEGF</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Growth factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-214</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PDRG1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Oncogene</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-218</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">BMI1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Oncogene</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LASP1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Oncogene</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">miR-221</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Down or up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">TRAIL</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ATM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">DNA repair</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MDM2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Ubiquitin ligase targeting TP53</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">STMN1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Microtubule dynamics</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-222</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PTEN</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tumor suppressor gene</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-223</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TP53</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Proliferation, apoptosis, angiogenesis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-224</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SUFU</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tumor suppressor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">miR-23a/b</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">MAPK1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell growth, adhesion, survival, differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">EGFR</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell proliferation, differentiation, motility, survival</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MET</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Oncogene, growth factor receptor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ZEB1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B184-genes-08-00339">184</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-24</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CARD10</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FOXM1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-26a</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">HMGA1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Non-histone chromosomal protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PLOD2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Collagen crosslinking enzyme</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B187-genes-08-00339">187</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-27a</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SLC7A11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cystine/glutamate exchanger</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RUNX1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">miR-27b</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">DROSHA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR biogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">EGFR</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell proliferation, differentiation, motility, survival</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MET</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Oncogene, growth factor receptor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-27a-3p</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EGFR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, differentiation, motility, survival</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">miR-29a/b/c</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">Down or up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">PDGFRA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Growth factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MCL1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">DNMT3A/B</td>
<td align="center" colspan="1" rowspan="1" valign="middle">DNA methyltransferase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CDK6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cyclin-dependent protein kinase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">miR-30a/c</td>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">PLCG</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Actin organization, cell migration</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MAPK1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell growth, adhesion, survival, differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PDGFA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Growth factor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ATM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">DNA repair</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">TP53</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Proliferation, apoptosis, angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">NOTCH1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell signaling</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-31</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-320a/c</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ITGB3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell adhesion</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CDK6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cyclin-dependent protein kinase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">miR-34a</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NOTCH1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell signaling</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>,<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CD44</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell adhesion</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HNF4G</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nuclear receptor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-424</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EGFR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell proliferation, differentiation, motility, survival</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">mir-449a</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CDK6</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RB control</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CDC25a</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RB control</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TP130</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RB control</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-485-5p</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HMGA2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Non-histone chromosomal proteins</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-490-5p</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FOS</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Oncogene, transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-493</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">FZD4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Transmembrane receptor</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RhoC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">G protein</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">miR-497</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">BIRC5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">WNT7A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell signaling</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-574-3p</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MESDC1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mesoderm development</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-576-3p</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CCND1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cyclin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-590-3p</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TFAM</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mitochondrial transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">miR-7</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SHC1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell signaling</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PKC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kinase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B181-genes-08-00339">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HOXB5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Homeobox, transcription factor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B184-genes-08-00339">184</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-708</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CASP2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">miR-9</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Up</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CDH-1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B185-genes-08-00339">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CBX7</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Chromatin structure, transcription repression</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CERS2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell signaling</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-96</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CDKN1A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-99a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FGFR3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cell cycle control; angiogenesis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B17-genes-08-00339">17</xref>,<xref ref-type="bibr" rid="B173-genes-08-00339">173</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>* To avoid a long list of articles, References (Refs) refer to recent and comprehensive reviews and one scientific article about miR and BC. The reader can find more information in the shown bibliography. miR are reported using the names found in the references and related original articles, thus reflecting different types of nomenclature used in this field.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>